

Management of in-stent restenosis

Fernando Alfonso^{1*}, MD; J.J. Coughlan^{2,3,4,5}, MD, MB, BCh; Daniele Giacoppo^{3,4,5,6}, MD, MSc, PhD; Adnan Kastrati^{2,3,7}, MD; Robert A. Byrne^{4,5}, PhD, MB, BCh

1. Department of Cardiology, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, IIS-IP, CIBER-CV, Madrid, Spain; 2. Deutsches Herzzentrum München und Technische Universität München, Munich, Germany; 3. Department of Cardiology, ISAResearch, German Heart Center, Munich, Germany; 4. Cardiovascular Research Institute, Mater Private Network, Dublin, Ireland; 5. School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland; 6. Department of Cardiology, Alto Vicentino Hospital, Santorso, Italy; 7. German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany

F. Alfonso and J.J. Coughlan equally contributed to this manuscript and share joint first authorship.

A. Kastrati and R.A. Byrne are recognised as joint senior authors on this manuscript.

This paper also includes supplementary data published online at: <https://eurointervention.pronline.com/doi/10.4244/EIJ-D-21-01034>

KEYWORDS

- bare metal stent
- drug-eluting balloon
- drug-eluting stent
- in-stent restenosis

Abstract

In-stent restenosis (ISR) remains the most common cause of stent failure after percutaneous coronary intervention (PCI). Recent data suggest that ISR-PCI accounts for 5-10% of all PCI procedures performed in current clinical practice. This State-of-the-Art review will primarily focus on the management of ISR but will begin by briefly discussing diagnosis and classification. We then move on to detail the evidence base underpinning the various therapeutic strategies for ISR before finishing with a proposed ISR management algorithm based on current scientific data.

*Corresponding author: Department of Cardiology, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, IIS-IP, CIBER-CV, Calle de Diego de León 62, 28006 Madrid, Spain. E-mail: falf@hotmail.com

Abbreviations

BA	balloon angioplasty
BMS	bare metal stent
BVS	bioresorbable vascular scaffolds
CABG	coronary artery bypass grafting
CTO	chronic total occlusion
DCB	drug-coated balloon
DES	drug-eluting stent
ELCA	excimer laser coronary atherectomy
ISR	in-stent restenosis
IVBT	intravascular brachytherapy
IVI	intravascular imaging
IVL	intravascular lithotripsy
IVUS	intravascular ultrasound
LLL	late lumen loss
LMS	left main stem
MLD	minimal lumen diameter
OCT	optical coherence tomography
PCI	percutaneous coronary intervention
RA	rotational atherectomy
RCT	randomised controlled trial
TLR	target lesion revascularisation

Introduction

In-stent restenosis (ISR) is characterised by a significant reduction in the luminal diameter within the stented segment after a successful percutaneous coronary intervention (PCI) and remains the most common cause of stent failure^{1,2}. While the relative incidence of ISR has reduced with newer drug-eluting stent (DES) technologies in comparison to the bare metal stent (BMS) era^{3,4}, treatment of ISR still accounts for 5-10% of all PCI procedures performed in clinical practice^{5,6}. In this State-of-the-Art review, we will comprehensively discuss current evidence-based strategies for the management of ISR in contemporary interventional practice.

In-stent restenosis

Traditionally, ISR has been defined as a reduction $\geq 50\%$ of the luminal diameter within the previously stented segment or the vessel segments 5 mm proximal and distal to the stent (the “stent edges”), as assessed by coronary angiography⁷. Using intravascular imaging (IVI), which acquires data in three dimensions, ISR has been defined as a re-narrowing of $\geq 75\%$ of the reference vessel area in cross-section⁸. This definition follows that of classical autopsy studies, which also usually define ISR as a pathological vessel re-narrowing $\geq 75\%$ of the reference vessel area in cross-section^{9,10}. However, ISR can also be considered as a pathophysiological continuum and can therefore also be reported using continuous parameters. This continuous pathophysiological approach may be better suited for comparisons of the relative anti-restenotic efficacy of stent- and balloon-based treatment modalities.

The term “clinical restenosis” is sometimes used to refer to ISR associated with symptoms or signs of ischaemia¹¹. Given that not all ISR results in symptoms or signs of ischaemia (referred to as

“silent restenosis”), rates of clinical restenosis are consequently lower than overall rates of ISR. Similarly to *de novo* coronary artery disease (CAD), percutaneous interventional treatment of ISR may be indicated for patients presenting with either acute coronary syndrome (ACS) or chronic coronary syndrome (CCS).

RELEVANCE OF ISR IN MODERN INTERVENTIONAL PRACTICE

ISR can be considered the “Achilles heel” of modern PCI. In the United States (US), recent data has suggested that treatment of ISR may account for up to 10% of all PCI procedures performed, whereas in Europe it has been reported to constitute $\sim 5\%$ of all PCI procedures^{5,6}. ISR is recognised to be challenging to manage. Although ISR lesions can appear to be straightforward to treat percutaneously (and are nearly universally associated with angiographic success), they are associated with a high risk of recurrent clinical events after treatment, including recurrent target lesion revascularisation (TLR). ISR can also frequently present clinically as an ACS, with associated morbidity and mortality^{5,12}. Therefore, the development of strategies to prevent and optimally manage ISR is an important challenge for interventional cardiologists, with the potential to improve patient outcomes and to reduce morbidity and mortality.

ANGIOGRAPHIC CLASSIFICATION

The most commonly used ISR classification system was proposed by Mehran et al¹³ according to angiographic patterns. This system classified patients with BMS-ISR into groups based on three characteristics: ISR length (≤ 10 mm: focal, >10 mm: diffuse), ISR location (within or beyond stent borders) and occlusion (yes or no). Application of this classification system results in four main groups: Type I: focal; Type II: diffuse, within stent; Type III: diffuse, within and beyond stent; and Type IV: occlusive¹³. In this study, late angiographic surveillance was not required but the different angiographic patterns were associated with prognostic value with regard to the subsequent need for TLR¹³. This classification was based on BMS-ISR and therefore may not be as relevant for DES-ISR, where a greater proportion of ISR is focal in nature¹⁴. In addition, this classification is based only on angiographic appearances and therefore provides no information about the underlying pathophysiological mechanisms of ISR. The types of interventional treatment used in this study (balloon angioplasty [BA], stent alone, rotational atherectomy [RA] \pm stent, and excimer laser coronary angioplasty [ELCA] \pm stent) varied widely between the four ISR types and it is important to consider that this may also have contributed to the differences observed in rates of subsequent TLR¹³.

Mechanisms of ISR

ISR is an umbrella term which can refer to a wide variety of underlying pathophysiological processes. Therefore, a key step in any ISR treatment algorithm is the determination of the underlying mechanisms¹⁵. Several contributory mechanisms may coexist

simultaneously¹⁶ and all should be identified and addressed if possible during the ISR therapeutic procedure.

Potential mechanical or technical factors associated with ISR include stent undersizing, stent underexpansion, vessel calcification, stent fracture, and geographic miss^{17,18}. Biological mechanisms of ISR include neointimal hyperplasia and neoatherosclerosis¹⁹. Neointimal hyperplasia is defined as the accumulation of smooth muscle cells and extracellular matrix in the intima. Neoatherosclerosis is characterised by an accumulation of lipid-laden foamy macrophages, with or without necrotic core formation, and/or calcification within the neointima^{20,21}. Calcified neoatherosclerosis can be particularly challenging to manage and this finding may have relevance for decisions regarding percutaneous intervention^{22,23}.

ISR may be attributed to a variable degree of influence of 3 categories of factors in the stented coronary artery: extra-stent factors (i.e., which prevent adequate stent expansion like vessel calcification or multiple stent layers), stent-related factors (i.e., stent undersizing, stent fracture) and intra-stent factors (i.e., excessive tissue proliferation within the stent). These factors can coexist simultaneously and are summarised in **Figure 1**.

MECHANISMS OF ISR: BMS-ISR VS DES-ISR

Despite the obvious superficial commonalities, current evidence suggests that BMS-ISR and DES-ISR could be considered as distinct pathological entities¹⁹. This paradigm may be supported by the recognised differences between the two conditions with regard to angiographic appearances, time course of late lumen loss

(LLL), IVI morphology, histopathology, and clinical response to interventions^{10,16,19,20}. These differences are summarised in **Table 1**. Therefore, knowing whether the originally implanted stent was a BMS or DES is very useful when managing ISR.

Table 1. Comparison of the principal imaging and histological features of restenotic tissue after drug-eluting stent and bare metal stent implantation.

	Bare metal stent restenosis	Drug-eluting stent restenosis
Imaging features		
Angiographic morphology	Diffuse pattern more common	Focal pattern more common
OCT tissue properties	Homogenous, high signal band most common	Layered structure or heterogenous most common
Time course of late luminal loss	Late loss maximal by 6-8 months	Ongoing late loss out to 5 years
Histopathological features		
Smooth muscle cellularity	Rich	Hypocellular
Proteoglycan content	Moderate	High
Peri-strut fibrin and inflammation	Occasional	Frequent
Complete endothelialisation	3-6 months	Up to 48 months
Thrombus present	Occasional	Occasional
Neoatherosclerosis	Relatively infrequent, late	Relatively frequent, accelerated course
OCT: optical coherence tomography		




Figure 1. Factors to consider when performing ISR-PCI. ISR may be attributed to a variable degree of influence of 3 categories of factors in the stented coronary artery: extra-stent factors, stent-related factors and intra-stent factors. ISR: in-stent restenosis; PCI: percutaneous coronary intervention

Traditionally, it has been reported that neointimal hyperplasia is encountered more frequently in BMS-ISR, whereas in DES-ISR, neoatherosclerosis is more common. However, this may be an oversimplification and it has been demonstrated that optical coherence tomography (OCT) findings suggestive of neoatherosclerosis are less common in DES-ISR within the first year post-PCI (early DES-ISR) compared to DES-ISR which develops after 1 year post-PCI (late DES-ISR)²⁴⁻²⁶. In fact, a key factor in the difference in OCT findings observed between BMS-ISR and DES-ISR appears to be the timing of the ISR development associated with the two stent types, with BMS-ISR tending to develop earlier after PCI. Neo-atherosclerotic ISR appears to develop in tandem with native atherosclerotic disease progression, suggesting similar underlying mechanisms. However, neoatherosclerosis demonstrates an accelerated course in comparison to *de novo* atherosclerotic CAD²⁷.

An intravascular ultrasound (IVUS)-based study reported that, of BMS-ISR lesions, 69% had dominant neointimal hyperplasia, 14% had dominant stent underexpansion, and 8% had co-dominant pathologies. In DES-ISR, 59% of lesions had dominant tissue proliferation, 18% had dominant stent underexpansion and 16% had co-dominant pathologies¹⁶. In that study, a cut-off value of <5 mm² stent cross-sectional area (CSA) at the minimal lumen area (MLA) site was used to define stent underexpansion and

a value of 50% percentage neointimal hyperplasia at the MLA site was used to define dominant intimal hyperplasia¹⁶. In the same study, 40% of second-generation DES-ISR lesions had a stent CSA of <5 mm² and 66% had >50% neointimal hyperplasia, indicating both pathologies are commonly encountered in second-generation DES-ISR^{16,28}. However, a key limitation of this study was that it used greyscale IVUS and so could not evaluate the frequency of neoatherosclerosis.

TIME COURSE OF ISR

The time course of ISR after stent implantation appears to be dependent on the underlying stent type and this may have relevance for the follow-up of patients post-coronary stent implantation. While BMS-ISR was recognised to peak within the first 6 months post-stent implantation, the incidence of DES-ISR appears to continue to increase steadily for several years after stent implantation as a result of different mechanisms, including accelerated neoatherosclerosis^{20,29-32}. It is important to consider that the incidence of ISR may also be dependent on the nature of the follow-up, with increased identification of “silent” ISR in patients who undergo routine angiographic surveillance.

CLINICAL PRESENTATION

ISR was initially considered to be a slowly progressive, relatively benign, pathological process. However, it is now increasingly recognised that ISR is not benign and can commonly present as an ACS^{33,34}. Many patients identified with ISR in clinical practice are found to have elevations in high-sensitivity troponin levels, fulfilling the current criteria for spontaneous myocardial infarction (MI)³⁵. In patients with DES-ISR, IVI has demonstrated acute plaque rupture and stent thrombosis (ST), highlighting that these pathologies can be part of the spectrum of ISR presentations. Neoatherosclerosis may represent the link between ISR and these conditions, which were previously considered to represent distinct clinical entities. Notably, ACS presentation has also been reported to confer a higher risk of recurrent major adverse cardiovascular events (MACE) and angiographic restenosis after ISR-PCI³⁶.

Imaging for ISR

IMAGING FOR ISR: STENT ENHANCEMENT

Enhanced fluoroscopic imaging techniques (i.e., StentBoost [Philips]), also known as “stent enhancement” techniques, have also been reported to be useful for the detection of inadequate stent expansion, demonstrating superior correlations for stent expansion measured by IVUS when compared with quantitative coronary angiography³⁷. Stent enhancement is useful to both identify stent fracture and stent underexpansion and can be easily and quickly performed in the cath lab.

IMAGING FOR ISR: INTRAVASCULAR IMAGING

IVI can overcome some of the diagnostic limitations of angiography and provide a wealth of further information to define and classify ISR. IVI enables not only a more accurate assessment of the

degree of ISR but also an appropriate identification of the underlying pathophysiological mechanisms^{16,17,38}. Expert consensus and guidelines recommend (Class IIa, Level B) the use of IVI in order to assess ISR^{39,40}. Given that IVI allows for more precise determination of the underlying mechanisms and patterns of ISR, it is plausible to assume that this would enable more targeted treatment (through appropriate device and interventional strategy selection) with consequently improved outcomes⁴¹. However, it is important to acknowledge that there are currently no randomised controlled trials (RCTs) supporting the differential treatment of ISR based on IVI appearances. In fact, there is a paucity of data on long-term outcomes following IVI-guided treatment of ISR and the majority of RCTs on the management of ISR did not mandate the use of IVI⁴²⁻⁴⁴. The two most common forms of IVI used in clinical practice are OCT and IVUS. Each has its own relative advantages and disadvantages in the management of ISR, which we will now briefly discuss.

INTRAVASCULAR IMAGING: OCT

OCT, with a wavelength of 1.3 µm and axial resolution of 12-15 µm, provides 10 times the spatial resolution of IVUS³⁹. For ISR, this allows uniquely detailed neointimal tissue characterisation and the identification of neoatherosclerosis^{19,45}. However, limitations of OCT include the need to use contrast media to ensure a blood-free field for image acquisition, which may be difficult to achieve in tight or ostial ISR lesions. Moreover, due to reduced tissue penetration with OCT compared to IVUS the external elastic lamina (EEL) cannot always be adequately identified, which can lead to difficulties with vessel sizing. This may be particularly challenging in patients with multiple metal stent layers. Although OCT requires the injection of higher volumes of contrast media, which may be proarrhythmogenic and increase the likelihood of post-procedural acute kidney injury, the occurrence of these complications is rare. As such, the advantages of OCT assessment are expected to outweigh the risk of complications in most patients with ISR.

Based on OCT appearances⁴⁶, ISR can be classified into four groups:

- Homogeneous: uniform high signal intensity, low back-scatter, typical of areas of high smooth muscle cell content
- Heterogeneous: mixed signal intensity, may represent presence of proteoglycan-rich neointimal or early neoatherosclerotic plaque
- Attenuated: superficial high signal intensity, high back-scatter, likely indicative of lipid-core plaque
- Layered: most frequently presenting as superficial high signal intensity with deep low signal intensity often in peri-strut areas

Examples of OCT tissue patterns of ISR are shown in **Figure 2**. A homogeneous tissue pattern on OCT imaging is often considered typical of early-onset BMS-ISR⁴⁶. The other three patterns (attenuated, layered and heterogeneous) may represent part of the neoatherosclerotic disease spectrum, which is more commonly seen in DES-ISR⁴⁶. However, it is important to consider that all




Figure 2. OCT images demonstrating distinct tissue patterns in patients with ISR. A-B) Demonstrate relatively homogeneous severe neointimal proliferation with some confined darker areas close to the underlying stent struts that are readily visualised (bright dots casting a dorsal shadow). C-F) Typical images of neointimal hyperplasia. In C and D, a bright superficial intima and a large lipid plaque (dark area with diffuse borders) is demonstrated obscuring the underlying stent struts. A potential diagnosis of an intimal layer infiltrated by macrophages should be considered. In E and F, neointimal hyperplasia with intracoronary thrombus is demonstrated. In E, the bright localised image with dorsal shadow (6-7 o'clock) is suggestive of clusters of macrophages. (* denotes wire artefact). ISR: in-stent restenosis; OCT: optical coherence tomography

four patterns have been reported in both DES-ISR and BMS-ISR and their prevalence may differ with the timing of the ISR⁴⁶. For example, while a homogenous tissue pattern may be considered typical of BMS-ISR, in very late BMS-ISR (>5 years post-stent implantation), a heterogenous tissue pattern has been reported to be more common⁴⁷. Similarly, in DES-ISR, OCT findings corresponding to neointimal hyperplasia become more common with increasing follow-up time post initial stent implantation^{24,25}. The tissue pattern may also vary along the length of the stent, with some segments showing a typical, healthy neointima and other segments displaying neointimal hyperplasia, which may in some cases be complicated (i.e., with plaque rupture).

CORRELATION BETWEEN IMAGING AND HISTOLOGY

The ISR IVI appearance is most likely representative of the underlying histopathology. A homogenous tissue appearance on OCT has been shown to correspond to neointima and fibrous connective tissue as a result of smooth muscle cell proliferation⁴⁸. Conversely, heterogenous tissue patterns are associated with increased fibrin depositions and loose connective tissue⁴⁸. In addition, large lipid pools have been detected in patients showing the typical lipidic pattern characteristic of neointimal hyperplasia²¹. Knowledge of the likely underlying histopathology may be useful to inform treatment choices⁴⁹. However, studies which assess whether selecting treatment modalities according to the underlying pathological appearance can lead to improved clinical outcomes are still required.

INTRAVASCULAR IMAGING: IVUS

IVUS results in deeper tissue penetration, in comparison to OCT, and a blood-free field is not required. Given that the wavelength of IVUS is ~50 μm with an axial resolution of 150 μm , detailed tissue characterisation is not possible. However, IVUS can still demonstrate several findings relevant to ISR, including neointimal hyperplasia, mature neointimal hyperplasia, stent underexpansion, stent undersizing, and vessel calcification^{16,17}. In addition, the EEL is usually well delineated, both at the reference segment and beyond the stent struts, allowing accurate vessel sizing. Virtual histology IVUS has also been used to demonstrate neointimal hyperplasia in both BMS-ISR and DES-ISR, although this technology is not widely used in clinical practice at present⁵⁰.

INTRACORONARY PHYSIOLOGY

Symptoms or documented ischaemia associated with the ISR lesion should be demonstrated before proceeding with repeat revascularisation. In the clinical setting, the use of intracoronary physiology is sometimes advocated to aid decision-making for patients with ISR of moderate severity or in patients who are oligo-symptomatic. However, there are limited data on the use of fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR) for the assessment of ISR⁵¹. Previously published data with one-year follow-up have suggested that conservative management of angiographically moderate (40-70%) ISR lesions with an FFR value of ≥ 0.75 is safe⁵². However, there are no randomised data supporting an FFR-guided ISR treatment strategy. In general, patients with ISR should go through the same diagnostic pathway as patients with *de novo* CAD.

Management of ISR

GENERAL PRINCIPLES

The general principles for the treatment of ISR do not differ significantly from those for the treatment of native coronary stenoses. However, the presence of an existing scaffold brings some additional considerations compared with *de novo* disease, and persistent issues leading to the original stent failure may need to be identified and addressed in order to avoid recurrence.

ANGIOGRAPHIC PERFORMANCE, ACUTE GAIN, AND LATE LUMINAL LOSS

Quantitative coronary angiography measures to assess and compare the relative anti-restenotic efficacy of stent- and balloon-based treatment modalities include minimum lumen diameter (MLD), percentage diameter stenosis (%DS), acute gain, and LLL. Acute gain is defined as the difference between the MLD pre-procedure and the MLD immediately post-procedure. LLL is defined as the difference between the MLD immediately post-procedure and the MLD at follow-up angiography. When treating ISR, the aim is to maximise acute gain and minimise LLL. The temporal pattern of acute gain and LLL after PCI is shown in **Figure 3**. An important point is that drug-coated balloon (DCB) therapy is associated with reduced acute gain and reduced late loss compared to DES PCI, which is generally associated with increased




Figure 3. Acute gain and late luminal loss in ISR-PCI. When treating ISR, the aim is to maximise acute gain and minimise LLL. The most important parameter when comparing DESs and DCBs for the treatment of ISR is net gain. DES: drug-eluting stent; DCB: drug-coated balloon; ISR: in-stent restenosis; LLL: late lumen loss; PCI: percutaneous coronary intervention

acute gain but also increased late loss. As such, the most important parameter when comparing the two modalities is net gain, as shown in **Figure 3**, although minimal lumen diameter or %DS at late follow-up may be also used.

It is important to note that in the setting of ISR, acute gain and LLL will be impacted by not only the choice of treatment modality but also by extrinsic mechanical factors. A significant proportion of ISR lesions are associated with stent underexpansion, which may itself be secondary to vessel calcification. In addition, calcified neo-atherosclerotic ISR can also result in specific challenges with respect to achieving maximal acute gain^{22,23}. Indeed, it is noteworthy that in ISR treated with DES, primary stent underexpansion (i.e., underexpansion of the re-stenosed stent) has been associated with an increased risk of secondary stent underexpansion (i.e., underexpansion of the second stent used to treat the re-stenosed stent). This in turn has been associated with an increased risk of MACE and ISR recurrence^{17,18}. Post-procedural stent underexpansion has also been shown to predict recurrence for ISR treated with DCBs⁵³. These data could be interpreted as supporting the paradigm that failure to adequately address the root causes of ISR increases the future risk of recurrence. Indeed, suboptimal treatment of ISR can result in a vicious cycle, in which the risk of recurrence is increased and subsequent management becomes more and more challenging. This is of particular concern when patients are treated with an additional DES (the so-called “sandwich strategy”) leading to multiple stent layers or the “onion skin phenomenon”⁵⁴. Aggressively tackling mechanical factors prior to dedicated ISR treatment may help avoid this problem, although high quality evidence in this regard is limited.

THE EVIDENCE BASE FOR THE TREATMENT OF ISR

In recent years, numerous RCTs have been performed to determine the optimal management of ISR and these trials are summarised in

Supplementary Table 1, **Supplementary Table 2**, and **Figure 4**. A variety of treatment modalities have been compared directly in head-to-head studies and indirectly in network meta-analyses. When all of these treatment strategies have been compared using network meta-analysis, two modalities have consistently emerged as pre-eminent for the management of ISR: DES implantation and treatment with DCBs^{55,56}. These are the two therapeutic strategies recommended by current revascularisation guidelines⁴⁰. Rather than providing an exhaustive historical review of all the different therapeutic strategies that have been studied over the past few decades, this review will initially focus on these two treatments for ISR before discussing adjunctive therapeutic modalities.

The results of several of the largest ISR trials (trials with >200 patients enrolled) are demonstrated in **Figure 5**. These are divided into 5 research themes: intravascular brachytherapy trials, rotational atherectomy trials, DES trials, DCB trials, and DES vs DCB trials. The outcome of interest highlighted in this figure is MACE.

Systematic review methods

In order to identify trials comparing treatments for ISR, a literature search was performed in PubMed at the time of the writing of this document. The search strategy is reported in **Supplementary Appendix 1**. The reference lists from the identified papers and previous meta-analyses on ISR were also reviewed in order to identify any other related studies. Only RCTs comparing therapeutic modalities in patients with coronary ISR are included in **Supplementary Table 1**, **Supplementary Table 2**, and **Figure 4**.

Drug-eluting stents

DESs are recognised for their strong anti-proliferative properties³⁴ and are therefore very attractive for the management of ISR. Indeed, DESs have superseded BMSs for the treatment of *de novo* CAD based on their lower restenosis rates³⁴. Network meta-analyses have ranked DES implantation as the most effective treatment for ISR^{55,56}. In addition, head-to-head trials have demonstrated the superiority of DES implantation to several other therapeutic modalities for ISR, including BA^{42,57,58}, intravascular brachytherapy (IVBT)⁵⁹⁻⁶¹, and paclitaxel DCBs⁶². A potential drawback of DES implantation is that another layer of stent is implanted. This can lead to subsequent therapeutic challenges in the event of ISR recurrence. As such, care must be taken to ensure adequate lesion preparation has been achieved prior to implantation of a new DES for the treatment of ISR, with particular care taken to tackle any underexpansion of the original stent. **Figure 6** and **Figure 7** demonstrate the use of a DES to treat ISR with evidence of ruptured neoatherosclerosis in the LAD (left anterior descending coronary artery). In the case of stent fracture, re-stenting will be required in the majority of cases.

DES STRATEGY: HETERO-DES VS HOMO-DES

One specific subtopic of interest with regard to DES treatment for DES-ISR is the choice of anti-proliferative agent. It has been




Figure 4. Trials assessing the treatment of ISR. The size of the circles corresponds to the size of the trial. The colour of the circles' perimeter indicates the underlying stent type in the ISR population studied. The inner colour of the circle indicates the interventional strategies used in the trial, corresponding to the coloured bars at the top of the figure. The length of the coloured bars at the top of the figure indicates the time span during which each therapeutic modality has been studied for the treatment of ISR. Detailed descriptions of the studies and the randomised arms are provided in Supplementary Table 1. BMS: bare metal stent; DES: drug-eluting stent; ISR: in-stent restenosis

hypothesised that treating DES-ISR using a DES with an alternative anti-proliferative agent (the “hetero-DES” strategy) might provide superior outcomes to using a DES with the same anti-proliferative agent (the “homo-DES” strategy). This hypothesis is based on the concept that drug resistance may have played a role in the development of the initial DES-ISR. However, evidence in this regard has been mixed. The only randomised trial on this topic, ISAR DESIRE-2, did not show a benefit to the hetero-DES strategy for the treatment of sirolimus-eluting stent ISR⁴³. Alternatively, the RIBS-III study had suggested a hetero-DES strategy may provide superior outcomes, although this study was not randomised and the alternative treatment decisions were at the discretion of local investigators⁶³. A meta-analysis has suggested that there may be a benefit to a hetero-DES strategy but this included results from several observational analyses, limiting the validity of the findings⁶⁴. Paclitaxel DESs are no longer available and large studies

comparing the potential value of implanting a hetero-DES with a different -limus drug have not been performed.

Drug-coated balloons

DCB catheters are comprised of standard angioplasty balloons and a matrix coating that is applied to the surface of the balloon⁶⁵. The balloon coating is typically comprised of two elements: a lipophilic active drug and a spacer or excipient which increases the solubility of the active drug and facilitates its transfer from the balloon surface to the vessel wall⁶⁵.

DCBs provide anti-proliferative therapy without the requirement for an additional metallic scaffold. This technology is intuitively attractive for the management of ISR as it avoids multiple stent layers. DCBs may be particularly useful for clinical situations where the addition of another stent layer is undesirable (i.e., multiple previous stent layers, the presence of a major side branch) and




Figure 5. Clinical outcomes in major ISR trials. ISR trials with over 200 patients enrolled are divided into 5 research themes: intravascular brachytherapy trials, rotational atherectomy trials, DES trials, DCB trials, and DES vs DCB trials. MACE is the outcome of interest displayed for each trial. Three ISR trials with >200 patients enrolled are not shown in this figure: These are RIBS I (Bare Metal Stent vs Balloon Angioplasty), RESCUT (Balloon Angioplasty vs Cutting Balloon) and OSIRIS (Placebo vs Normal Dose Sirolimus vs High Dose Sirolimus). Details of all ISR trials identified in our search are provided in Supplementary Table 1 and Supplementary Table 2. BA: balloon angioplasty; DCB: drug-coated balloons; DES: drug-eluting stent; DES-E: everolimus-eluting stent; DES-P: paclitaxel-eluting stent; DES-S: sirolimus-eluting stent; DES-Z: zotarolimus-eluting stent; ISR: in-stent restenosis; IVBT: intravascular brachytherapy; MACE: major adverse cardiac events; NSB: non-slip balloon; SB: scoring balloon; UHPNCB: ultra-high-pressure non-compliant balloon

may be particularly suited to clinical situations where the mechanism of ISR is stent maldeployment. In addition, patients treated with DCBs generally require a more abbreviated dual antiplatelet therapy (DAPT) regimen and therefore this strategy may be particularly useful in patients at high bleeding risk.

PACLITAXEL DCBs

Initial commercially available DCBs eluted paclitaxel and the majority of clinical evidence relates to the use of paclitaxel-coated DCBs, particularly those based on iopromide⁶⁶⁻⁶⁸. Paclitaxel was used in preference to other drugs in DCBs due to its lipophilic

properties. RCTs have demonstrated the superiority of DCB therapy to several other treatment modalities for ISR, including BA and BMS implantation^{44,69-71}. There is limited evidence comparing paclitaxel DCBs with different excipient coatings, although one small study suggested that outcomes are similar between iopromide and butyryl-tri-hexyl citrate-coated DCBs⁷².

Of note, concern was raised in a 2018 meta-analysis regarding excess mortality associated with paclitaxel-coated balloons and stents in femoropopliteal disease⁷³. However, several subsequent studies have questioned these findings in peripheral arterial disease^{74,75}. Importantly, in the setting of CAD, the use of paclitaxel




Figure 6. An 81-year-old man presented with prolonged chest pain (15 minutes) 12 years after the implantation of a DES in the proximal LAD. The ECG was normal but a rise in high-sensitivity troponins was detected. A-E) OCT images from the distal part of the stent (A) to the LAD ostium (E) are shown. F) The longitudinal OCT display depicting the location of the corresponding cross-sections. The distal part of the stent (A, B) showed a mild neointimal hyperplasia (with a homogeneous bright yellow colour) and an excellent residual coronary lumen (* denotes wire artefact). Alternatively, the proximal part of the stent (C-D) showed ruptured neoatherosclerosis with intracoronary thrombus (C, F). There is a ruptured cap with associated thrombus (C) and bright neointima (D, E) overlying a large lipid plaque (dark areas with undefined edges), which completely obscure (shadowing) most of the underlying stent struts. The broken arrows indicate the area which demonstrates obstructive neoatherosclerosis (F). DES: drug-eluting stent; ECG: electrocardiogram; ISR: in-stent restenosis; LAD: left anterior descending coronary artery; LCX: left circumflex coronary artery; LM: left main; OCT: optical coherence tomography

DCBs has never been linked with safety issues or excesses in mortality. Further reassuring information in this regard was recently provided by a large meta-analysis⁷⁶.

SIROLIMUS DCBs

In recent years, sirolimus DCBs have also been developed and initial registry data has demonstrated encouraging results in both

de novo CAD and ISR^{77,78}. Given that network meta-analysis has suggested that -limus-eluting DESs are associated with superior outcomes compared to paclitaxel-eluting DESs for the treatment of ISR⁵⁶, it could be hypothesised that similar advantages might exist when comparing the two DCB technologies for the treatment of ISR. Until very recently, the technology to ensure adequate binding, persistence and transfer of -limus-based drugs from




Figure 7. OCT findings (A-F) in the same patient as in Figure 6, after treatment of the ISR with repeat DES implantation. The location of the cross-section images (A-E, top) is illustrated in the longitudinal display (F, bottom). A) Distal untreated segment of the previous stent. B-E) Treated segment (yellow arrow) demonstrating the 2 stent layers. There is also a significant protrusion of soft irregular material into the coronary lumen. (* denotes wire artefact). DES: drug-eluting stent; ISR: in-stent restenosis; LAD: left anterior descending coronary artery; LCX: left circumflex coronary artery; LM: left main; OCT: optical coherence tomography

DCBs to the arterial wall did not exist. However, recent technological advances have enabled the development of -limus DCBs. Notwithstanding the potential attractiveness of -limus DCBs for the treatment of ISR, evidence on their safety and effectiveness in this scenario still remains limited. A small RCT comparing a novel sirolimus DCB balloon to a paclitaxel DCB reported similar 6-month angiographic and 12-month clinical outcomes in the two groups⁷⁹. Of note, there are no published randomised data comparing sirolimus DCBs vs DESs for the treatment of ISR. In the future, larger studies will be useful to determine the relative efficacy of sirolimus DCBs compared to both paclitaxel DCBs and DESs. It is important to recognise that there is insufficient evidence currently to support the concept of a “class effect” for both limus- and paclitaxel-eluting DCBs and further research would be useful in this regard.

DCB: THE IMPORTANCE OF LESION PREPARATION

Adequate lesion preparation is paramount when treating ISR, irrespective of the final proposed treatment modality. The efficacy of a DCB relies on rapid initial drug transfer of the anti-proliferative drug and subsequent tissue retention in the restenotic area. Therefore, the use of cutting or scoring balloons to impact on the ISR obstructive tissue prior to DCB treatment may help to improve the delivery of the anti-proliferative agent. The ISAR-DESIRE 4 trial demonstrated that neointimal modification with a scoring balloon improved the anti-restenotic efficacy of DCB therapy⁸⁰. Interestingly, a drug-coated scoring balloon has been developed, combining both treatment modalities in one device. This has shown promising results in initial studies when compared to an uncoated scoring balloon alone⁸¹, though it should be acknowledged that the sequential use of the devices might be the most efficacious approach.

DES VS DCB FOR THE TREATMENT OF ISR: DIRECT EVIDENCE

Several studies have compared DESs to paclitaxel DCBs for ISR⁶⁸⁻⁷⁸. Despite the theoretical advantages of DCBs in the management of ISR, a meta-analysis of randomised controlled data comparing DES versus paclitaxel-DCB angioplasty has demonstrated that repeat DES implantation for ISR is moderately more effective in reducing the rate of TLR at 3 years⁵². In this setting, repeat DES implantation provides better acute angiographic results than DCB treatment, including increases in the MLD and reductions in residual %DS. In most head-to-head RCTs, these superior acute angiographic results with DES as compared with DCB treatments are maintained at longer-term follow-up. The DAEDALUS study, a meta-analysis of patient-level data from 10 RCTs which included 1,976 patients, demonstrated that DESs reduced the need for subsequent TLR compared with paclitaxel DCBs at 3 years⁶². Of interest, it appears that the relative efficacy of these two treatments for ISR may depend on the underlying stent type^{82,83}. In patients with BMS-ISR, clinical efficacy and safety outcomes appear to be comparable with both DESs

and DCBs⁸³. Given that a DCB provides comparable efficacy without the need for an additional stent layer, this strategy may therefore be preferable in this setting. Conversely for the more challenging scenario of DES-ISR, repeat stenting with a DES is moderately more effective compared to treatment with a DCB regarding the need for TLR⁸³. However, this increased efficacy must be weighed against the implantation of an additional stent layer. Importantly, irrespective of the selected treatment modality, the treatment of BMS-ISR is associated with superior late angiographic and clinical outcomes in comparison to the treatment of DES-ISR⁸⁴.

Adjunctive therapeutic modalities for ISR

While current evidence supports DCBs and DESs as the optimal initial treatment modalities for ISR in the majority of cases, other treatment modalities may still have a complementary or adjunctive role. This may be particularly the case for recurrent ISR. In this section, we will discuss the evidence base and potential niche roles for these adjunctive ISR treatments. Given the varied and challenging nature of ISR disease, it may be useful for specialist centres performing complex ISR interventions to have several adjunctive treatment options in their armamentarium.

BALLOON ANGIOPLASTY

BA was the earliest treatment available for ISR but was subsequently shown to be inferior to multiple newer alternative treatment modalities^{42,44,69}. BA results in some acute gain due to tissue extrusion (both longitudinal and axial) in addition to stent expansion⁸⁵. However, this acute gain is often short lived, with tissue re-intrusion occurring shortly after the last balloon inflation⁸⁶. In addition, this strategy is plagued by recurrent severe tissue proliferation and has been virtually abandoned in Europe as a definitive therapy. In the US, where DCBs have still not been approved, isolated conventional BA is still used for cases with focal ISR where the risk of recurrence is deemed to be low. In the setting of an underdeployed stent, non-compliant or ultra-high-pressure non-compliant balloons (UHPNCBs) at high pressures should be used to improve stent expansion. However, based on current data, isolated BA is not routinely recommended for the treatment of ISR and this technique is best regarded as a method for lesion preparation prior to the use of other therapies or for final optimisation of DES implantation.

CUTTING/SCORING BALLOONS

Cutting balloons are comprised of standard balloon catheters mounted with lateral metallic blades, which on inflation of the balloon incise into the treated stenotic plaque. Scoring balloons have a broadly similar mechanistic basis but employ low-profile nitinol wires (of the order of 125 µm) on the surface of the balloon catheter in a spiral formation.

The two main advantages to their use are that the incision of the blades into the stenotic plaque may favour subsequent tissue extrusion and the interaction of the blades with the plaque serves

to anchor the balloon in the plaque. Both cutting and scoring balloons may play a valuable role in lesion preparation prior to DESs or DCBs in the treatment of ISR⁸⁷. However, as a standalone treatment, both technologies are hindered by their inability to inhibit neointimal proliferation and suffer from similar limitations to BA^{88,89}. In the ISAR-DESIRE 4 trial, the use of a scoring balloon prior to a DCB has been shown to improve the anti-restenotic efficacy of the DCB⁸⁰. Cutting/scoring balloons may also be useful to avoid the “watermelon seeding” phenomenon that can occur when dilating ISR lesions, particularly in the presence of severe or diffuse patterns of ISR⁹⁰. “Watermelon seeding” is associated with prolonged procedure times, suboptimal acute angiographic results and inferior long-term outcomes. It can result in “geographic miss”, which can subsequently lead to recurrent edge-ISR. A non-slip element balloon has also shown similar efficacy to high-pressure non-compliant balloons in lesion preparation pre-DCB treatment for ISR⁹¹.

INTRAVASCULAR BRACHYTHERAPY

IVBT refers to the delivery of localised radiation within the stent. The aim of this treatment modality is to impede neointimal cell growth within the target area without damage to the surrounding tissue. The radiation achieves this effect via two primary methods: direct damage secondary to ionising emissions and injury secondary to free radical generation⁹². Several randomised clinical trials demonstrated that IVBT was superior to the mechanical alternatives available at the time⁹³⁻⁹⁵. When DESs became available, they rapidly superseded IVBT due to both their greater simplicity and superior results in the setting of BMS-ISR⁵⁹⁻⁶¹. However, there are no randomised data on the use of IVBT in the setting of DES-ISR. Observational analysis has suggested that IVBT may have a role in recurrent ISR⁹⁶⁻⁹⁸. This lack of evidence has prevented the common use of this technology in modern practice, where IVBT has been abandoned in most centres.

ABLATIVE STRATEGIES

Commercially available ablative technologies for the management of ISR include RA and ELCA. Historically, these technologies were attractive for the management of ISR as they had the ability to ablate the restenotic tissue that obstructs the stent. While some of the early results in this regard were promising, when ablative strategies were compared to alternative treatment modalities, the results at late follow-up did not show any significant benefit compared to control. Therefore, their routine and systematic use for the management of ISR was abandoned. However, they may still play a niche role in the management of undilatable ISR lesions when other conventional strategies have failed, particularly when managing calcified neoatherosclerotic ISR.

ABLATIVE STRATEGIES: EXCIMER LASER CORONARY ATHERECTOMY

ELCA is a debulking technique which uses ultraviolet spectrum wavelengths to ablate tissue⁹⁹. It does this by generating heat and

shockwaves¹⁰⁰. Despite some early historical studies demonstrating the safety and feasibility of this technique¹⁰¹, there are limited recent data to support the systematic use of ELCA as the primary treatment for ISR and no randomised data are available on the use of ELCA for DES-ISR. However, in selected cases it may have an adjunctive role for lesion preparation¹⁰², particularly for recurrent ISR in the setting of severe calcification. For the rarely encountered patients with undilatable ISR as the result of severely underexpanded stents due to a heavily calcified arterial wall, this technique may facilitate stent expansion, particularly if contrast is injected to induce further barotrauma and microcavitation. Evidence in this regard stems only from small observational series but it nevertheless remains a useful option as a bailout strategy when other therapeutic strategies have failed.

ABLATIVE STRATEGIES: ROTATIONAL ATHERECTOMY

RA is another ablative technique which can be used to debulk ISR lesions and facilitate the application of subsequent treatments (as part of a combined strategy). There are historical RCTs comparing RA to BA in BMS-ISR^{103,104}. While the ROSTER trial (that mandated the use of IVUS during the intervention) suggested superior results with RA compared to BA, the much larger ARTIST trial reported inferior results with RA and a higher number of procedural-related complications^{103,104}. However, it should be noted that this may have been related to the trial protocol, which mandated lower balloon inflation pressures in the RA arm of this study, and to the lack of systematic IVUS use to rule out severe underexpansion. There are no randomised data for the use of RA in the treatment of DES-ISR. However, it may still have a role as an adjunctive technique for lesion preparation prior to DCB application or recurrent DES implantation^{22,105,106}. It should be considered a high-risk procedure and particular care must be taken to avoid burr entrapment within the ISR lesion^{22,106}. The successful use of RA to ablate metal (“stentablation”/“rotastenting”) in the exceedingly rare cases of severely underexpanded and undilatable stents has also been reported. However, this procedure has obvious inherent potential risks (burr entrapment, vessel perforation), and indications for its use are likely to be extremely restricted, given that more attractive and safer strategies are now available to tackle this unique problem (see below).

INTRAVASCULAR LITHOTRIPSY

Intravascular lithotripsy (IVL) is a relatively new technology which uses localised pulsatile sound waves to circumferentially modify vascular calcium¹⁰⁷. IVL has been demonstrated to be safe and effective in *de novo* CAD¹⁰⁸. The use of IVL to facilitate stent expansion in ISR has been described but there are limited data available on this technique and it is regarded as an off-label use¹⁰⁹⁻¹¹². However, many observational reports have demonstrated that IVL may be used with success in patients with undilatable ISR resistant to conventional strategies, especially in the setting of stent underexpansion due to circumferential coronary artery calcification¹¹³. In a manner similar to ELCA, the energy produced

modifies the compliance of the calcified plaque causing fractures beyond or within the stent. Compared with ELCA and RA, the use of IVL in patients with ISR is much more user friendly and less dependent on operator experience.

BARE METAL STENTS

BMS implantation was used after BA for the treatment of BMS-ISR and showed some promise in terms of acute luminal gain compared to BA¹¹⁴. However, in the RIBS-I trial, BMS implantation failed to show an advantage at 6-month follow-up in comparison to BA for the treatment of BMS-ISR¹¹⁵. In that study, BMSs were superior to conventional BA only in the predefined subset of patients with large (≥ 3 mm) vessels. BMSs also proved to be superior to BA in patients presenting with edge-ISR¹¹⁶. There are no trials assessing the value of BMSs for the treatment of DES-ISR and as such, their role in the management of ISR is largely historical.

BIORESORBABLE VASCULAR SCAFFOLDS

Bioresorbable vascular scaffolds (BVS) were considered potentially attractive for the treatment of ISR. However, the use of BVS for patients with ISR was associated with a higher TLR rate in comparison to results obtained with DESs in previous studies^{117,118}. Polymeric BVS are no longer commercially available¹¹⁹. The potential value of magnesium-based BVS (Mg-BVS) has been investigated in some early preliminary studies^{120,121}, but further research is required to determine whether they will play a future role in the treatment of patients with ISR.

MANAGEMENT OF PATIENTS WITH BVS-ISR

The RIBS VII study prospectively registered the treatment of patients with BVS-ISR¹²². Overall and after adjusting for potential confounders, patients with BVS-ISR had similar clinical outcomes to patients with restenosis of metallic stents.

CORONARY ARTERY BYPASS GRAFTING

Coronary artery bypass grafting (CABG) may be a reasonable treatment option in selected patients, but there are no RCTs comparing CABG to other treatment modalities for ISR. However, some observational analyses have reported that patients treated with CABG for ISR (85% of whom had multivessel disease) had superior outcomes compared to percutaneous therapies¹²³. CABG may also be considered in patients with (1) ISR of the left main stem (LMS)¹²⁴, (2) recalcitrant ISR in a major vessel, (3) associated multivessel disease, or (4) ISR located in the ostial LAD.

ADJUNCTIVE MEDICAL THERAPY

The use of several adjunctive anti-inflammatory or anti-proliferative medications has been suggested for patients with ISR, in particular for patients presenting with recurrent ISR. It was hypothesised that the use of adjunctive medical therapies would reduce the risk of ISR recurrence. In the OSIRIS study, oral sirolimus resulted in a significant improvement in 6-month angiographic parameters¹²⁵. However, this early benefit was attenuated

at longer follow-up and concern regarding potential side effects led to reduced interest in this therapy¹²⁶. Currently there is no clear evidence supporting the use of adjunctive systemic anti-proliferative medical treatments in these patients.

Specific clinical scenarios

Some specific clinical scenarios with relevance for ISR include recurrent ISR, ISR in the setting of severe calcification, LMS ISR, ISR chronic total occlusion (CTO), and stent fracture.

RECURRENT ISR

Recurrent ISR refers to ISR that has recurred after the initial treatment of ISR. If the ISR was initially treated with repeat implantation of a stent, this means that the recurrent ISR lesion will have two stent layers. Some ISR lesions may have more than two stent layers. These cases appear to be systematically associated with underexpansion of the initial stent. ISR-PCI with a DCB has been associated with worse outcomes for patients with three layers of stent than for those with one or two stent layers¹²⁷. Therefore, it may be advisable to avoid a third layer of stent when treating recurrent ISR, although DES implantation has been reported to be safe and effective in recurrent ISR with two stent layers¹²⁸. Another study reported that DES implantation was superior to BA in patients with recurrent ISR previously treated with a DES¹²⁹. However, there are limited dedicated randomised data available to guide treatment decisions in this challenging lesion subset. IVBT has been reported to be a useful modality for recurrent ISR with multiple stent layers but a meta-analysis suggests that TVR still occurs in approximately 1 in 4 patients at 2 years in this setting^{96,97}. DCBs may also be useful in this challenging setting although the 1-year TLR incidence was reported as 14.5% in the 1-stent layer group, 14.9% in the 2-stent layer group and 41.2% in the 3-stent layer group in a study by Yabushita et al¹²⁷.

When managing recurrent ISR, it is particularly important to determine if there are persistent mechanical issues which were not adequately addressed during the initial ISR therapeutic procedure, and which may have contributed to the ISR recurrence. Failure to deal with these persistent mechanical issues will likely increase the risk of future TLR. In most cases underexpanded stents appear to represent the trigger for recurrence, although localised stent fractures (i.e., at hinge points) may also contribute to recurrence in some cases¹³⁰. Ensuring optimal final stent expansion is of paramount importance in this scenario. Whether the systematic use of IVL in these patients will help to improve clinical results in patients with recurrent ISR remains to be determined. Finally, as discussed earlier, CABG should be considered in patients with recurrent ISR affecting the LMS or the ostial LAD, and in patients with multivessel disease.

ISR IN THE SETTING OF SEVERE CALCIFICATION AND STENT UNDEREXPANSION

Coronary artery calcification is a recognised major risk factor for ISR. For ISR in the setting of calcification and stent

underexpansion, calcium modification may be required. RA, ELCA, IVL¹⁰⁹⁻¹¹² and UHPNCBs can all be used to modify calcium and facilitate stent expansion in this setting^{101,105,106,131}. Repeat IVI following calcium modification may be useful to ensure it has been successful, particularly if definitive therapy with DES implantation is planned. There are limited data comparing the various calcium modification strategies and the choice will likely depend on both local availability and skill set. If this cannot be performed locally, referral to a specialist centre may be mandated. Ideally, specialised ISR tertiary referral centres should have several calcium modification modalities available to ensure the widest array of ISR lesions can be treated.

LEFT MAIN STEM ISR

There are limited data on the management of LMS ISR¹³². The FAILS study reported that LMS ISR could be managed percutaneously in the majority of cases¹³³. A retrospective analysis has also suggested that DES and DCB treatments can provide similar outcomes in this setting¹³⁴. However, a high mortality after TLR for LMS stent failure has been reported¹³⁵, and CABG should be considered in suitable patients.

ISR-CTO

ISR-CTO was suggested to represent its own distinct class of ISR in the Mehran classification¹³. ISR-CTO PCI has been associated with a higher risk of complications and adverse events during follow-up in comparison to CTO-PCI in some reports^{136,137}. However, other studies have reported comparable results to *de novo* CTO-PCI¹³⁸⁻¹⁴⁰.

Visualisation of the stent in different projections during the ISR-CTO PCI procedure provides a roadmap that may facilitate advancement of special wires within the true lumen. Procedural outcomes may be impacted by operator experience and ISR-CTO PCI should be regarded as a highly specialised, high-risk procedure.

STENT FRACTURE

Stent fracture may be identified in association with ISR¹⁴¹⁻¹⁴³ and is generally defined as complete or incomplete separation of the stent strut on angiography and/or the absence of a stent strut on at least one slice on IVUS^{141,142}. For ISR lesions secondary to stent fracture, repeat stenting will be required in the majority of cases, although it must be acknowledged that there is an absence of high-quality, randomised data to support this recommendation.

ISR treatment algorithm

Based on the data discussed in this review, we present a proposed ISR treatment algorithm. It should be noted that this algorithm is intended for managing restenosis within the stent, rather than edge-restenosis, which will require repeat stenting in the majority of cases.

When we consider the scientific evidence summarised in this review, it appears that two of the most important factors to consider

when deciding how to treat ISR are the stent type implanted during the index procedure (BMS or DES) and the presence or absence of mechanical issues preventing adequate stent expansion. This is because the optimal treatment for ISR (DES or DCB) appears to be impacted by the underlying stent type, and failure to adequately address mechanical issues appears to increase the risk of future ISR recurrence^{17,83}.

Mechanical issues are best identified using IVI and, consistent with current guidelines, we would recommend the use of IVI for all ISR cases^{39,40,144}. The use of enhanced fluoroscopic imaging techniques (i.e., StentBoost) may also be useful in particular to identify mechanical issues like stent fracture and stent underexpansion.

Based on the IVI findings, the operator can then decide how best to address mechanical issues (if present) and prepare the ISR lesion. Adequate lesion preparation is an important determinant of procedural success and should be dictated by both the presumed underlying pathology and the local skill set. IVI can also be repeated following lesion preparation to ensure mechanical issues have been addressed prior to more definitive therapy. If IVI is not available, operators should focus on adequately predilating the ISR lesion and optimising stent expansion. This may include the use of non-compliant balloons and UHPNCBs. Cutting/scoring balloons can also be useful and should be used prior to DCB therapy where possible in order to optimise DCB efficacy.

The operator can then decide how to treat the lesion. Given the available scientific evidence, DCBs or DESs should be used to treat ISR in the majority of cases. In some cases, suboptimal results (i.e., significant dissections or persistent residual stenosis >40%) are observed despite multiple attempts at predilatation. In these cases, the use of DCBs as definitive treatment may yield similar results to the initial balloon predilatation and therefore DESs should be used preferentially¹⁴⁵. Repeat DES implantation is moderately more effective than DCBs for DES-ISR and so could be considered the favoured treatment modality in this setting. Similarly, if the underlying stent type is not known, operators should favour DESs given that they have been shown to be moderately more effective than DCB therapy overall for the management of ISR. However, operators need to balance this moderate efficacy benefit against the implantation of another stent layer. As such, in some cases initial treatment with DCBs could be preferable, for instance if there are already two layers of stent present. Given that DCB and DES implantation have comparable outcomes in BMS-ISR, DCB may be preferable in the first instance. Other factors may also impact on clinical decision-making in this regard (i.e., presence of a significant side branch). In patients with high bleeding risk, the use of DCBs may also facilitate a more abbreviated duration of DAPT.

Repeat IVI post-treatment should usually be performed to determine if an acceptable procedural result has been achieved. If not, further measures may be required to optimise the result and this process can be repeated until a satisfactory result is achieved. An algorithm summarising these recommendations is demonstrated in

Figure 8.




Figure 8. Algorithm for the management of in-stent restenosis.

*Mechanical issues can include stent undersizing, stent underexpansion, vessel calcification, stent fracture, and geographic miss. Mechanical issues can be addressed via a variety of methods dependent on the identified pathology and local skill set. These methods can include BA, RA, ELCA, IVL, UHPNCB, cutting, and scoring balloons. **Predilatation can be performed with BA, UHPNCB, cutting, or scoring balloons. Cutting and scoring balloons may be particularly useful prior to planned DCB therapy. BA: balloon angioplasty; BMS: bare metal stent; DCB: drug-coated balloon; DES: drug-eluting stent; ELCA: excimer laser coronary atherectomy; ISR: in-stent restenosis; IVI: intravascular imaging; IVL: intravascular lithotripsy; RA: rotational atherectomy; UHPNCB: ultra-high-pressure non-compliant balloons

For recurrent ISR, previously attempted interventions should be reviewed (if possible) prior to managing the recurrence. This should include determining if mechanical factors were adequately identified and treated during the previous ISR treatment procedure.

Future interventional paradigms

In our proposed treatment algorithm for ISR, we suggest that the decision regarding the optimal treatment modality can be guided by the underlying restenotic stent type (BMS or DES). This interventional paradigm is based on currently available randomised data. However, it has also been speculated that the tissue causing the ISR may play a role in predicting the response to different therapeutic strategies. OCT in particular provides unique insights, not only to identify mechanical factors predisposing to ISR, but also to gain further knowledge of the tissue (ISR substrate) within the stent. Guidance of ISR treatment according to the underlying

ISR tissue type would also be appealing within a personalised medicine paradigm. However, there are limited data to support this hypothesis at present. A recent observational analysis has suggested that the ISR tissue pattern (heterogenous or homogenous) observed on OCT could also potentially be useful to guide treatment¹⁴⁶. This preliminary study suggested that in patients with heterogenous ISR on OCT, DESs showed an advantage over DCBs. No such advantage was seen in patients with a homogenous pattern on OCT. Replication of these results in prospective RCTs may lead to a future ISR interventional paradigm in which treatment decisions can be algorithmically guided based on ISR tissue patterns on OCT. Indeed, this hypothesis will be examined by the upcoming ISAR-DESIRE 5 trial, an RCT with a factorial design randomising patients with homogenous and heterogenous ISR tissue patterns on OCT to either DCB or DES treatment. Until then, the treatment of patients with ISR should be based on current scientific data, as outlined in **Figure 8**.

Optimal follow-up and treatment after ISR-PCI FOLLOW-UP

ISR is recognised as being challenging to treat, with high rates of recurrence at medium- to long-term follow-up. Despite this, there are limited data to guide the optimal follow-up of patients after ISR-PCI. Routine control angiography after ISR-PCI is one potential strategy to identify recurrent restenosis, although this approach has not been assessed in RCTs and might lead to an increase in the number of repeated revascularisations without clinical indication. Routine control angiography has the potential benefit of enabling the identification of “silent restenosis” and has been shown to provide prognostic information after index PCI procedures³⁴. However, in the absence of RCT evidence, follow-up after ISR-PCI should primarily consist of clinical follow-up aimed at identifying signs or symptoms of recurrent ischaemia, which could be suggestive of ISR recurrence. Given that patients undergoing ISR-PCI have been shown to have a significant event rate at late follow-up, higher than that associated with *de novo* lesion PCI, clinical surveillance should be continued beyond one year after ISR-PCI^{147,148}. In addition, evidence-based secondary prevention measures should be implemented, with aggressive management of cardiovascular risk factors.

DAPT DURATION AFTER ISR-PCI

Currently, there is insufficient evidence to suggest that patients undergoing PCI for ISR require a different DAPT composition and duration to patients undergoing PCI for *de novo* lesions. In general, DAPT composition (i.e., the use of conventional or more potent P2Y₁₂ inhibitors) and duration should be guided by the clinical presentation of patients with ISR. Of note, patients treated with DCB will, in general, require a shorter duration of DAPT in comparison to patients treated with DES. However, it is also important to recognise that currently there is insufficient evidence that DAPT composition and duration should be guided by the type of PCI (DCB or DES) for ISR.

A subanalysis of the PRODIGY trial has suggested that a prolonged DAPT regimen (24 months) may be beneficial for patients undergoing ISR-PCI compared to an abbreviated DAPT regimen (6 months), although this requires confirmation in larger, dedicated trials¹⁴⁹. A final important point is that, although not specifically evaluated for patients with PCI for ISR, evidence generated by recent antiplatelet therapy de-escalation trials is likely to also be valid for patients undergoing ISR-PCI.

In **Figure 9**, we present a summary of the "do's and don'ts" of ISR-PCI. These heuristic guidelines may provide operators with some useful "rules of thumb" to follow when performing ISR-PCI. While each ISR procedure will have its own unique considerations, these principles will be broadly applicable to the vast majority of cases encountered in clinical practice. The major principles of managing ISR are highlighted in the **Central illustration**.

Conclusions

Despite recent advances in PCI, ISR remains a significant issue and the most common cause of stent failure, accounting for 5-10% of all PCI procedures in modern clinical practice.

While the relative rate of ISR has been reduced with newer-generation DESs in comparison to the BMS era, increasing procedural volume and complexity has resulted in a higher absolute number of ISR-PCI procedures being performed in modern practice.

Current evidence suggests that DESs or DCBs are the optimal treatment modalities for the majority of ISR cases.

IVI can provide useful information to guide treatment decisions in ISR-PCI, and future ISR interventional paradigms may be guided by IVI ISR tissue patterns.

Conflict of interest statement

The authors have no conflicts of interest to declare.

References

- Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. *J Am Coll Cardiol*. 2010;56:1897-907.
- Alfonso F, Byrne RA, Rivero F, Kastrati A. Current treatment of in-stent restenosis. *J Am Coll Cardiol*. 2014;63:2659-73.
- Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabaté M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schömig A. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. *N Engl J Med*. 2007;356:1030-9.
- Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. *Lancet*. 2007;370:937-48.
- Moussa ID, Mohanane D, Saucedo J, Stone GW, Yeh RW, Kennedy KF, Waksman R, Teirstein P, Moses JW, Simonton C. Trends and Outcomes of Restenosis After Coronary Stent Implantation in the United States. *J Am Coll Cardiol*. 2020;76:1521-31.
- Alfonso F, Kastrati A. Clinical burden and implications of coronary interventions for in-stent restenosis. *EuroIntervention*. 2021;17:e355-7.
- Kuntz RE, Baim DS. Defining coronary restenosis. Newer clinical and angiographic paradigms. *Circulation*. 1993;88:1310-23.
- Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014. *Eur Heart J*. 2015;36:3320-31.
- Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. *J Am Coll Cardiol*. 2006;48:193-202.
- Nakano M, Otsuka F, Yahagi K, Sakakura K, Kutys R, Ladich ER, Finn AV, Kolodgie FD, Virmani R. Human autopsy study of drug-eluting stents restenosis: histomorphological predictors and neointimal characteristics. *Eur Heart J*. 2013;34:3304-13.
- Cutlip DE, Chauhan MS, Baim DS, Ho KK, Popma JJ, Carrozza JP, Cohen DJ, Kuntz RE. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. *J Am Coll Cardiol*. 2002;40:2082-9.





Figure 9. Do's and Don'ts of ISR-PCI. BMS: bare metal stent; DCB: drug-coated balloon; DES: drug-eluting stent; ISR: in-stent restenosis; PCI: percutaneous coronary intervention

CENTRAL ILLUSTRATION A summary of the major principles of managing ISR.

First, the ISR lesion should be identified and defined using IVI. The lesion should then be prepared using balloon dilatation. High-pressure, cutting or scoring balloons can be used as required. Mechanical factors contributing to ISR should be addressed. This may require adjunctive modalities, including RA, ELCA, and IVL, depending on local expertise. Once the lesion has been adequately prepared, treatment with a DES or DCB should be used for the majority of cases. DESs are moderately more effective than DCBs in DES-ISR. For BMS-ISR, DCBs and DESs are comparatively effective and so DCBs should be considered preferentially. After PCI, IVI should be considered to confirm a satisfactory result has been achieved. BMS: bare metal stent; DCB: drug-coated balloon; DES: drug-eluting stent; ELCA: excimer laser coronary atherectomy; ISR: in-stent restenosis; IVI: intravascular imaging; IVL: intravascular lithotripsy; PCI: percutaneous coronary intervention; RA: rotational atherectomy

12. Assali AR, Moustapha A, Sdringola S, Denktas AE, Willerson JT, Holmes DR Jr, Smalling RW. Acute coronary syndrome may occur with in-stent restenosis and is associated with adverse outcomes (the PRESTO trial). *Am J Cardiol.* 2006;98:729-33.
13. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. *Circulation.* 1999;100:1872-8.
14. Solinas E, Dangas G, Kirtane AJ, Lansky AJ, Franklin-Bond T, Boland P, Syros G, Kim YH, Gupta A, Mintz G, Fahy M, Collins M, Kodali S, Stone GW, Moses JW, Leon MB, Mehran R. Angiographic patterns of drug-eluting stent restenosis and one-year outcomes after treatment with repeated percutaneous coronary intervention. *Am J Cardiol.* 2008;102:311-5.
15. Shlofmitz E, Iantorno M, Waksman R. Restenosis of Drug-Eluting Stents: A New Classification System Based on Disease Mechanism to Guide Treatment and State-of-the-Art Review. *Circ Cardiovasc Interv.* 2019;12:e007023.
16. Goto K, Zhao Z, Matsumura M, Dohi T, Kobayashi N, Kirtane AJ, Rabbani LE, Collins MB, Parikh MA, Kodali SK, Leon MB, Moses JW, Mintz GS, Maehara A. Mechanisms and Patterns of Intravascular Ultrasound In-Stent Restenosis Among Bare Metal Stents and First- and Second-Generation Drug-Eluting Stents. *Am J Cardiol.* 2015;116:1351-7.
17. Fujii K, Mintz GS, Kobayashi Y, Carlier SG, Takebayashi H, Yasuda T, Moussa I, Dangas G, Mehran R, Lansky AJ, Reyes A, Kreps E, Collins M, Colombo A, Stone GW, Teirstein PS, Leon MB, Moses JW. Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. *Circulation.* 2004;109:1085-8.
18. Yin D, Mintz GS, Song L, Chen Z, Lee T, Kirtane AJ, Parikh MA, Moses JM, Fall KN, Jeremias A, Ali ZA, Shlofmitz RA, Maehara A, Collaborators. In-stent restenosis characteristics and repeat stenting underexpansion: insights from optical coherence tomography. *EuroIntervention.* 2020;16:e335-43.
19. Byrne RA, Joner M, Tada T, Kastrati A. Restenosis in bare metal and drug-eluting stents: distinct mechanistic insights from histopathology and optical intravascular imaging. *Minerva Cardioangiol.* 2012;60:473-89.
20. Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, Kolodgie FD, Finn AV, Virmani R. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. *J Am Coll Cardiol.* 2011;57:1314-22.
21. Otsuka F, Byrne RA, Yahagi K, Mori H, Ladich E, Fowler DR, Kutys R, Xhepa E, Kastrati A, Virmani R, Joner M. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. *Eur Heart J.* 2015;36:2147-59.
22. Bastante T, Rivero F, Cuesta J, Alfonso F. Calcified Neoatherosclerosis Causing "Undilatable" In-Stent Restenosis: Insights of Optical Coherence Tomography and Role of Rotational Atherectomy. *JACC Cardiovasc Interv.* 2015;8:2039-40.
23. Garcia-Guimaraes M, Antuña P, Maruri-Sanchez R, Vera A, Cuesta J, Bastante T, Rivero F, Alfonso F. Calcified neoatherosclerosis causing in-stent restenosis: prevalence, predictors, and implications. *Coron Artery Dis.* 2019;30:1-8.
24. Kang SJ, Mintz GS, Akasaka T, Park DW, Lee JY, Kim WJ, Lee SW, Kim YH, Whan Lee C, Park SW, Park SJ. Optical coherence tomographic analysis of in-stent neoatherosclerosis after drug-eluting stent implantation. *Circulation.* 2011;123:2954-63.
25. Habara M, Terashima M, Nasu K, Kaneda H, Yokota D, Ito T, Kurita T, Teramoto T, Kimura M, Kinoshita Y, Tsuchikane E, Asakura Y, Suzuki T. Morphological differences of tissue characteristics between early, late, and very late restenosis lesions after first generation drug-eluting stent implantation: an optical coherence tomography study. *Eur Heart J Cardiovasc Imaging.* 2013;14:276-84.
26. Kilickesmez K, Dall'Ara G, Rama-Merchan JC, Ghione M, Mattesini A, Vinues CM, Konstantinidis N, Pighi M, Estevez-Loureiro R, Zivelonghi C, Lindsay AC, Secco GG, Foin N, De Silva R, Di Mario C. Optical coherence tomography characteristics of in-stent restenosis are different between first and second generation drug eluting stents. *Int J Cardiol Heart Vessel.* 2014;3:68-74.
27. Taniwaki M, Windecker S, Zaugg S, Stefanini GG, Baumgartner S, Zanchin T, Wenaweser P, Meier B, Jüni P, Räber L. The association between in-stent neoatherosclerosis and native coronary artery disease progression: a long-term angiographic and optical coherence tomography cohort study. *Eur Heart J.* 2015;36:2167-76.
28. Kang SJ, Mintz GS, Park DW, Lee SW, Kim YH, Whan Lee C, Han KH, Kim JJ, Park SW, Park SJ. Mechanisms of in-stent restenosis after drug-eluting stent implantation: intravascular ultrasound analysis. *Circ Cardiovasc Interv.* 2011;4:9-14.
29. Kastrati A, Schömig A, Dietz R, Neumann FJ, Richardt G. Time course of restenosis during the first year after emergency coronary stenting. *Circulation.* 1993;87:1498-505.

30. Kimura T, Nosaka H, Yokoi H, Iwabuchi M, Nobuyoshi M. Serial angiographic follow-up after Palmaz-Schatz stent implantation: comparison with conventional balloon angioplasty. *J Am Coll Cardiol*. 1993;21:1557-63.
31. Byrne RA, Iijima R, Mehilli J, Piniack S, Bruskin O, Schömig A, Kastrati A. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. *JACC Cardiovasc Interv*. 2009;2:291-9.
32. Räber L, Wohlwend L, Wigger M, Togni M, Wandel S, Wenaweser P, Cook S, Moschovitis A, Vogel R, Kalesan B, Seiler C, Eberli F, Lüscher TF, Meier B, Jüni P, Windecker S. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. *Circulation*. 2011;123:2819-28.
33. Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare metal stent restenosis is not a benign clinical entity. *Am Heart J*. 2006;151:1260-4.
34. Casse S, Byrne RA, Schulz S, Hoppman P, Kreutzer J, Feuchtenberger A, Ibrahim T, Ott I, Fusaro M, Schunkert H, Laugwitz KL, Kastrati A. Prognostic role of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting. *Eur Heart J*. 2015;36:94-9.
35. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). *J Am Coll Cardiol*. 2018;72:2231-64.
36. Magalhaes MA, Minha S, Chen F, Torguson R, Omar AF, Loh JP, Escarcega RO, Lipinski MJ, Baker NC, Kitabata H, Ota H, Suddath WO, Satler LF, Pichard AD, Waksman R. Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations. *Circ Cardiovasc Interv*. 2014;7:768-76.
37. Mishell JM, Vakharia KT, Ports TA, Yeghiazarians Y, Michaels AD. Determination of adequate coronary stent expansion using StentBoost, a novel fluoroscopic image processing technique. *Catheter Cardiovasc Interv*. 2007;69:84-93.
38. Alfonso F, Sandoval J, Cárdenas A, Medina M, Cuevas C, Gonzalo N. Optical coherence tomography: from research to clinical application. *Minerva Med*. 2012;103:441-64.
39. Räber L, Mintz GS, Koskinas KC, Johnson TW, Holm NR, Onuma Y, Radu MD, Joner M, Yu B, Jia H, Meneveau N, de la Torre Hernandez JM, Escaned J, Hill J, Prati F, Colombo A, di Mario C, Regar E, Capodanno D, Wijns W, Byrne RA, Guagliumi G; ESC Scientific Document Group. Clinical use of intracoronary imaging. Part I: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. *Eur Heart J*. 2018;39:3281-300.
40. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferović PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO. 2018 ESC/EACTS Guidelines on myocardial revascularization. *EuroIntervention*. 2019;14(14):1435-534.
41. Buccheri S, Franchina G, Romano S, Puglisi S, Venuti G, D'Arrigo P, Francaviglia B, Scalia M, Condorelli A, Barbanti M, Capranzano P, Tamburino C, Capodanno D. Clinical Outcomes Following Intravascular Imaging-Guided Versus Coronary Angiography-Guided Percutaneous Coronary Intervention With Stent Implantation: A Systematic Review and Bayesian Network Meta-Analysis Of 31 Studies and 17,882 Patients. *JACC Cardiovasc Interv*. 2017;10:2488-98.
42. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schühlen H, Schmitt C, Dirschinger J, Schömig A; ISAR-DESIRE Study Investigators. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. *JAMA*. 2005;293:165-71.
43. Mehilli J, Byrne RA, Tiroch K, Piniack S, Schulz S, Kufner S, Massberg S, Laugwitz KL, Schömig A, Kastrati A; ISAR-DESIRE 2 Investigators. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. *J Am Coll Cardiol*. 2010;55:2710-6.
44. Byrne RA, Neumann FJ, Mehilli J, Piniack S, Wolff B, Tiroch K, Schulz S, Fusaro M, Ott I, Ibrahim T, Hausleiter J, Valina C, Pache J, Laugwitz KL, Massberg S, Kastrati A; ISAR-DESIRE 3 investigators. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. *Lancet*. 2013;381:461-7.
45. Malle C, Tada T, Steigerwald K, Ughi GJ, Schuster T, Nakano M, Massberg S, Jehle J, Guagliumi G, Kastrati A, Virmani R, Byrne RA, Joner M. Tissue characterization after drug-eluting stent implantation using optical coherence tomography. *Arterioscler Thromb Vasc Biol*. 2013;33:1376-83.
46. Gonzalo N, Serruys PW, Okamura T, van Beusekom HM, Garcia-Garcia HM, van Soest G, van der Giessen W, Regar E. Optical coherence tomography patterns of stent restenosis. *Am Heart J*. 2009;158:284-93.
47. Habara M, Terashima M, Nasu K, Kaneda H, Inoue K, Ito T, Kamikawa S, Kurita T, Tanaka N, Kimura M, Kinoshita Y, Tsuchikane E, Matsuo H, Ueno K, Katoh O, Suzuki T. Difference of tissue characteristics between early and very late restenosis lesions after bare-metal stent implantation: an optical coherence tomography study. *Circ Cardiovasc Interv*. 2011;4:232-8.
48. Kim JS, Afari ME, Ha J, Tellez A, Milewski K, Conditt G, Cheng Y, Hua Yi G, Kaluza GL, Granada JF. Neointimal patterns obtained by optical coherence tomography correlate with specific histological components and neointimal proliferation in a swine model of restenosis. *Eur Heart J Cardiovasc Imaging*. 2014;15:292-8.
49. Tada T, Kadota K, Hosogi S, Miyake K, Ohya M, Amano H, Izawa Y, Kanazawa T, Kubo S, Ichinohe T, Hyoudou Y, Hayakawa Y, Sabbah MM, Otsuru S, Hasegawa D, Habara S, Tanaka H, Fuku Y, Katoh H, Goto T, Mitsudo K. Association between tissue characteristics assessed with optical coherence tomography and mid-term results after percutaneous coronary intervention for in-stent restenosis lesions: a comparison between balloon angioplasty, paclitaxel-coated balloon dilatation, and drug-eluting stent implantation. *Eur Heart J Cardiovasc Imaging*. 2015;16:1101-11.
50. Kang SJ, Mintz GS, Park DW, Lee SW, Kim YH, Lee CW, Han KH, Kim JJ, Park SW, Park SJ. Tissue characterization of in-stent neointima using intravascular ultrasound radiofrequency data analysis. *Am J Cardiol*. 2010;106:1561-5.
51. Nam CW, Rha SW, Koo BK, Doh JH, Chung WY, Yoon MH, Tahk SJ, Lee BK, Lee JB, Yoo KD, Cho YK, Chung IS, Hur SH, Kim KB, Choi CU, Oh DJ. Usefulness of coronary pressure measurement for functional evaluation of drug-eluting stent restenosis. *Am J Cardiol*. 2011;107:1783-6.
52. Lopez-Palop R, Pinar E, Lozano I, Saura D, Picó F, Valdés M. Utility of the fractional flow reserve in the evaluation of angiographically moderate in-stent restenosis. *Eur Heart J*. 2004;25:2040-7.
53. Miura K, Tada T, Habara S, Kuwayama A, Shimada T, Ohya M, Murai R, Amano H, Kubo S, Otsuru S, Tanaka H, Fuku Y, Goto T, Kadota K. Optical Coherence Tomography Predictors for Recurrent Restenosis After Paclitaxel-Coated Balloon Angioplasty for Drug-Eluting Stent Restenosis. *Circ J*. 2018;82:2820-8.
54. Alfonso F, Scheller B. Management of recurrent in-stent restenosis: onion skin full metal jacket? *EuroIntervention*. 2013;9:781-5.
55. Giacoppo D, Gargiulo G, Aruta P, Capranzano P, Tamburino C, Capodanno D. Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. *BMJ*. 2015;351:h5392.
56. Siontis GC, Stefanini GG, Mavridis D, Siontis KC, Alfonso F, Pérez-Vizcayno MJ, Byrne RA, Kastrati A, Meier B, Salanti G, Jüni P, Windecker S. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. *Lancet*. 2015;386:655-64.
57. Alfonso F, Pérez-Vizcayno MJ, Hernandez R, Bethencourt A, Marti V, López-Mínguez JR, Angel J, Mantilla R, Moris C, Cequier A, Sabaté M, Escaned J, Moreno R, Bañuelos C, Suárez A, Macaya C; RIBS-II Investigators. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intra-stent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial. *J Am Coll Cardiol*. 2006;47:2152-60.
58. Chevalier B, Moullichon R, Teiger E, Brunel P, Metzger JP, Pansieri M, Carrie D, Stoll HP, Wittebols K, Spaulding C, Fajadet J; Cristal Investigators. One-year results of the CRISTAL Trial, a randomized comparison of cypher sirolimus-eluting coronary stents versus balloon angioplasty for restenosis of drug-eluting stents. *J Interv Cardiol*. 2012;25:586-95.
59. Holmes DR Jr, Teirstein P, Satler L, Sketch M, O'Malley J, Popma JJ, Kuntz RE, Fitzgerald PJ, Wang H, Caramanica E, Cohen SA; SISR Investigators. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. *JAMA*. 2006;295:1264-73.
60. Stone GW, Ellis SG, O'Shaughnessy CD, Martin SL, Satler L, McGarry T, Turco MA, Kereiakes DJ, Kelley L, Popma JJ, Russell ME. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. *JAMA*. 2006;295:1253-63.
61. Park SW, Lee SW, Koo BK, Park DW, Lee SW, Kim YH, Lee CW, Hong MK, Kim JJ, Mori K, Lansky AJ, Mintz GS, Lee MM, Park SJ. Treatment of diffuse in-stent restenosis with drug-eluting stents vs. intracoronary beta-radiation therapy: INDEED Study. *Int J Cardiol*. 2008;131:70-7.
62. Giacoppo D, Alfonso F, Xu B, Claessen B, Adriaenssens T, Jensen C, Pérez-Vizcayno MJ, Kang DY, Degenhardt R, Pleva L, Baan J, Cuesta J, Park DW, Schunkert H, Colleran R, Kukla P, Jiménez-Quevedo P, Unverdorben M, Gao R, Naber CK, Park SJ, Henriques JPS, Kastrati A, Byrne RA. Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). *Eur Heart J*. 2020;41:3715-28.

63. Alfonso F, Pérez-Vizcayno MJ, Dutary J, Zueco J, Cequier A, García-Touchard A, Martí V, Lozano I, Angel J, Hernández JM, López-Mínguez JR, Melgares R, Moreno R, Seidelberger B, Fernández C, Hernandez R; RIBS-III Study Investigators (under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology). Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]). *JACC Cardiovasc Interv.* 2012;5:728-37.
64. Vyas A, Schweizer M, Malhotra A, Karrowni W. Meta-analysis of same versus different stent for drug-eluting stent restenosis. *Am J Cardiol.* 2014;113:601-6.
65. Byrne RA, Joner M, Alfonso F, Kastrati A. Drug-coated balloon therapy in coronary and peripheral artery disease. *Nat Rev Cardiol.* 2014;11:13-23.
66. Habara S, Mitsudo K, Kadota K, Goto T, Fujii S, Yamamoto H, Katoh H, Oka N, Fuku Y, Hosogi S, Hirono A, Maruo T, Tanaka H, Shigemoto Y, Hasegawa D, Tasaka H, Kusunose M, Otsuru S, Okamoto Y, Saito N, Tsujimoto Y, Eguchi H, Miyake K, Yoshino M. Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. *JACC Cardiovasc Interv.* 2011;4:149-54.
67. Chen Y, Gao L, Qin Q, Chen S, Zhang J, Chen H, Wang L, Jin Z, Zheng Y, Zhang Z, Li H, Li X, Fu G, Chen L, Sun Z, Wang Y, Jin Q, Cao F, Guo J, Zhao Y, Guan C, Li W, Xu B; RESTORE ISR China Investigators. Comparison of 2 Different Drug-Coated Balloons in In-Stent Restenosis: The RESTORE ISR China Randomized Trial. *JACC Cardiovasc Interv.* 2018;11:2368-77.
68. Hamm CW, Dörr O, Woehrl J, Krackhardt F, Ince H, Zeus T, Berland J, Piot C, Roubille F, Schult I, Alocco DJ, Nef H. A multicentre, randomised controlled clinical study of drug-coated balloons for the treatment of coronary in-stent restenosis. *EuroIntervention.* 2020;16:e328-34.
69. Rittger H, Brachmann J, Sinha AM, Waliszewski M, Ohlow M, Brugger A, Thiele H, Birkemeyer R, Kurowski V, Breithardt OA, Schmidt M, Zimmermann S, Lonke S, von Cranach M, Nguyen TV, Daniel WG, Wöhrle J. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. *J Am Coll Cardiol.* 2012;59:1377-82.
70. Habara S, Iwabuchi M, Inoue N, Nakamura S, Asano R, Nanto S, Hayashi Y, Shiode N, Saito S, Ikari Y, Kimura T, Hosokawa J, Nakamura M, Kotani J, Kozuma K, Mitsudo K. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. *Am Heart J.* 2013;166:527-33.
71. Rittger H, Waliszewski M, Brachmann J, Hohenforst-Schmidt W, Ohlow M, Brugger A, Thiele H, Birkemeyer R, Kurowski V, Schlundt C, Zimmermann S, Lonke S, von Cranach M, Markovic S, Daniel WG, Achenbach S, Wöhrle J. Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With Sequent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter). *JACC Cardiovasc Interv.* 2015;8:1695-700.
72. Colleran R, Joner M, Kufner S, Altevogt F, Neumann FJ, Abdel-Wahab M, Bohner J, Valina C, Richardt G, Zrenner B, Cassese S, Ibrahim T, Laugwitz KL, Schunkert H, Kastrati A, Byrne RA; Intracoronary Stenting and Angiographic Results: Optimizing treatment of Drug Eluting Stent In-Stent Restenosis 3 and 4 (ISAR-DESIRE 3 and ISAR-DESIRE 4) investigators. Comparative efficacy of two paclitaxel-coated balloons with different excipient coatings in patients with coronary in-stent restenosis: A pooled analysis of the Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 3 and 4 (ISAR-DESIRE 3 and ISAR-DESIRE 4) trials. *Int J Cardiol.* 2018;252:57-62.
73. Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of Death Following Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *J Am Heart Assoc.* 2018;7:e011245.
74. Freisinger E, Koeppel J, Gerss J, Goerlich D, Malyar NM, Marschall U, Faldum A, Reinecke H. Mortality after use of paclitaxel-based devices in peripheral arteries: a real-world safety analysis. *Eur Heart J.* 2020;41:3732-9.
75. Nordanstig J, James S, Andersson M, Andersson M, Danielsson P, Gillgren P, Delle M, Engström J, Fransson T, Hamoud M, Hilbertson A, Johansson P, Karlsson L, Kragsterman B, Lindgren H, Ludwigs K, Mellander S, Nyman N, Renlund H, Sigvant B, Skoog P, Starck J, Tegler G, Toivola A, Truedson M, Wahlgren CM, Wallinder J, Öjersjö A, Falkenberg M. Mortality with Paclitaxel-Coated Devices in Peripheral Artery Disease. *N Engl J Med.* 2020;383:2538-46.
76. Scheller B, Vukadinovic D, Jeger R, Rissanen TT, Scholz SS, Byrne R, Kleber FX, Latib A, Clever YP, Ewen S, Böhm M, Yang Y, Lansky A, Mahfoud F. Survival After Coronary Revascularization With Paclitaxel-Coated Balloons. *J Am Coll Cardiol.* 2020;75:1017-28.
77. Cortese B, di Palma G, Latini RA, Elwany M, Orrego PS, Seregini RG. Immediate and short-term performance of a novel sirolimus-coated balloon during complex percutaneous coronary interventions. The FATEbenefatelli Sirolimus COated-balloon (FASICO) registry. *Cardiovasc Revasc Med.* 2017;18:487-91.
78. Verheye S, Vrolix M, Kumsars I, Erglis A, Sondore D, Agostoni P, Cornelis K, Janssens L, Maeng M, Slagboom T, Amoroso G, Jensen LO, Granada JF, Stella P. The SABRE Trial (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis): Angiographic Results and 1-Year Clinical Outcomes. *JACC Cardiovasc Interv.* 2017;10:2029-37.
79. Ali RM, Abdul Kader M, Wan Ahmad WA, Ong TK, Liew HB, Omar AF, Mahmood Zuhdi AS, Nuruddin AA, Schnorr B, Scheller B. Treatment of Coronary Drug-Eluting Stent Restenosis by a Sirolimus- or Paclitaxel-Coated Balloon. *JACC Cardiovasc Interv.* 2019;12:558-66.
80. Kufner S, Joner M, Schneider S, Tölg R, Zrenner B, Repp J, Starkmann A, Xhepa E, Ibrahim T, Cassese S, Fusaro M, Ott I, Hengstenberg C, Schunkert H, Abdel-Wahab M, Laugwitz KL, Kastrati A, Byrne RA; ISAR-DESIRE 4 Investigators. Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents: A Randomized Controlled Trial. *JACC Cardiovasc Interv.* 2017;10:1332-40.
81. Scheller B, Fontaine T, Mangner N, Hoffmann S, Bonaventura K, Clever YP, Chamie D, Costa R, Gershony G, Kelsch B, Kutschera M, Génereux P, Cremers B, Böhm M, Speck U, Abizaid A. A novel drug-coated scoring balloon for the treatment of coronary in-stent restenosis: Results from the multi-center randomized controlled PATENT-C first in human trial. *Catheter Cardiovasc Interv.* 2016;88:51-9.
82. Alfonso F, Pérez-Vizcayno MJ, García Del Blanco B, García-Touchard A, López-Mínguez JR, Sabaté M, Zueco J, Melgares R, Hernández R, Moreno R, Domínguez A, Sanchis J, Moris C, Moreu J, Cequier A, Romaguera R, Rivero F, Cuesta J, Gonzalo N, Jiménez-Quevedo P, Cárdenas A, Fernández C; Spanish Society of Cardiology. Usefulness of Drug-Eluting Balloons for Bare-Metal and Drug-Eluting In-Stent Restenosis (from the RIBS IV and V Randomized Trials). *Am J Cardiol.* 2017;119:983-90.
83. Giacoppo D, Alfonso F, Xu B, Claessen B, Adriaenssens T, Jensen C, Pérez-Vizcayno MJ, Kang DY, Degenhardt R, Pleva L, Baan J, Cuesta J, Park DW, Kukla P, Jiménez-Quevedo P, Unverdorben M, Gao R, Naber CK, Park SJ, Henriques JPS, Kastrati A, Byrne RA. Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis. *J Am Coll Cardiol.* 2020;75:2664-78.
84. Byrne RA, Cassese S, Windisch T, King LA, Joner M, Tada T, Mehilli J, Pache J, Kastrati A. Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials. *EuroIntervention.* 2013;9:797-802.
85. Mehran R, Mintz GS, Popma JJ, Pichard AD, Satler LF, Kent KM, Griffin J, Leon MB. Mechanisms and results of balloon angioplasty for the treatment of in-stent restenosis. *Am J Cardiol.* 1996;78:618-22.
86. Alfonso F, García P, Fleites H, Pimentel G, Sabaté M, Hernández R, Escaned J, Bañuelos C, Pérez-Vizcayno MJ, Moreno R, Macaya C. Repeat stenting for the prevention of the early lumen loss phenomenon in patients with in-stent restenosis. Angiographic and intravascular ultrasound findings of a randomized study. *Am Heart J.* 2005;149:e1-8.
87. Takano M, Yamamoto M, Murakami D, Takano H, Asai K, Yasutake M, Seino Y, Mizuno K. Optical coherence tomography after new scoring balloon angioplasty for in-stent restenosis and de novo coronary lesions. *Int J Cardiol.* 2010;141:e51-3.
88. Albiero R, Silber S, Di Mario C, Cernigliaro C, Battaglia S, Reimers B, Frasheri A, Klaus V, Auge JM, Rubartelli P, Morice MC, Cremonesi A, Schofer J, Bortone A, Colombo A; RESCUT Investigators. Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis: results of the restenosis cutting balloon evaluation trial (RESCUT). *J Am Coll Cardiol.* 2004;43:943-9.
89. Fasseas P, Orford JL, Lennon R, O'Neill J, Denktas AE, Panetta CJ, Berger PB, Holmes DR. Cutting balloon angioplasty vs. conventional balloon angioplasty in patients receiving intracoronary brachytherapy for the treatment of in-stent restenosis. *Catheter Cardiovasc Interv.* 2004;63:152-7.
90. Alfonso F, Pérez-Vizcayno MJ, Gómez-Recio M, Insa L, Calvo I, Hernández JM, Bullones JA, Hernández R, Escaned J, Macaya C, Gama-Ribeiro V, Leitao-Marques A; Restenosis Intra-stent: Balloon Angioplasty Versus Elective Stenting (RIBS) Investigators. Implications of the "watermelon seeding" phenomenon during coronary interventions for in-stent restenosis. *Catheter Cardiovasc Interv.* 2005;66:521-7.
91. Aoki J, Nakazawa G, Ando K, Nakamura S, Tobaru T, Sakurada M, Okada H, Hibi K, Zen K, Habara S, Fujii K, Habara M, Ako J, Asano T, Ozaki S, Fusazaki T, Kozuma K; ELEGANT Investigators. Effect of combination of non-slip element balloon and drug-coating balloon for in-stent restenosis lesions (ELEGANT study). *J Cardiol.* 2019;74:436-42.
92. Gruberg L, Waksman R. Intravascular radiation for the prevention of recurrence of restenosis in coronary arteries. *Expert Opin Investig Drugs.* 2001;10:891-907.

93. Waksman R, Cheneau E, Ajani AE, White RL, Pinnow E, Torguson R, Deible R, Satler LF, Pichard AD, Kent KM, Teirstein PS, Lindsay J; Washington Radiation for In-Stent Restenosis Trial for Long Lesions Studies. Intracoronary radiation therapy improves the clinical and angiographic outcomes of diffuse in-stent restenotic lesions: results of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions (Long WRIST) Studies. *Circulation*. 2003;107:1744-9.
94. Leon MB, Teirstein PS, Moses JW, Tripuraneni P, Lansky AJ, Jani S, Wong SC, Fish D, Ellis S, Holmes DR, Kerieakes D, Kuntz RE. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. *N Engl J Med*. 2001;344:250-6.
95. Teirstein PS, Massullo V, Jani S, Popma JJ, Mintz GS, Russo RJ, Schatz RA, Guarneri EM, Steuterman S, Morris NB, Leon MB, Tripuraneni P. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. *N Engl J Med*. 1997;336:1697-703.
96. Negi SI, Torguson R, Gai J, Kiramijyan S, Koifman E, Chan R, Randolph P, Pichard A, Satler LF, Waksman R. Intracoronary Brachytherapy for Recurrent Drug-Eluting Stent Failure. *JACC Cardiovasc Interv*. 2016;9:1259-65.
97. Megaly M, Glozoz M, Xenogiannis I, Vemmo E, Nikolakopoulos I, Omer M, Saad M, Willson L, Monyak DJ, Sullivan P, Pershad A, Chavez I, Mooney M, Traverse J, Wang Y, Garcia S, Poulouse A, Burke MN, Brilakis ES. Coronary Intravascular Brachytherapy for Recurrent Coronary Drug-Eluting Stent In-Stent Restenosis: A Systematic Review and Meta-Analysis. *Cardiovasc Revasc Med*. 2021;23:28-35.
98. Torguson R, Sabate M, Deible R, Smith K, Chu WW, Kent KM, Pichard AD, Suddath WO, Satler LF, Waksman R. Intravascular brachytherapy versus drug-eluting stents for the treatment of patients with drug-eluting stent restenosis. *Am J Cardiol*. 2006;98:1340-4.
99. Egred M, Brilakis ES. Excimer Laser Coronary Angioplasty (ELCA): Fundamentals, Mechanism of Action, and Clinical Applications. *J Invasive Cardiol*. 2020;32:E27-35.
100. Tsutsui RS, Sammour Y, Kalra A, Reed G, Krishnaswamy A, Ellis S, Nair R, Khatri J, Kapadia S, Puri R. Excimer Laser Atherectomy in Percutaneous Coronary Intervention: A Contemporary Review. *Cardiovasc Revasc Med*. 2021;25:75-85.
101. Mehran R, Dangas G, Mintz GS, Waksman R, Abizaid A, Satler LF, Pichard AD, Kent KM, Lansky AJ, Stone GW, Leon MB. Treatment of in-stent restenosis with excimer laser coronary angioplasty versus rotational atherectomy: comparative mechanisms and results. *Circulation*. 2000;101:2484-9.
102. Sato T, Tsuchida K, Yuasa S, Taya Y, Koshikawa T, Tanaka K, Fujita S, Ikeda Y, Takahashi M, Okabe M, Oda H, Aizawa Y. The effect of the debulking by excimer laser coronary angioplasty on long-term outcome compared with drug-coating balloon: insights from optical frequency domain imaging analysis. *Lasers Med Sci*. 2020;35:403-12.
103. vom Dahl J, Dietz U, Haager PK, Silber S, Niccoli L, Buettner HJ, Schiele F, Thomas M, Commeau P, Ramsdale DR, Garcia E, Hamm CW, Hoffmann R, Reineke T, Klues HG. Rotational atherectomy does not reduce recurrent in-stent restenosis: results of the angioplasty versus rotational atherectomy for treatment of diffuse in-stent restenosis trial (ARTIST). *Circulation*. 2002;105:583-8.
104. Sharma SK, Kini A, Mehran R, Lansky A, Kobayashi Y, Marmur JD. Randomized trial of Rotational Atherectomy Versus Balloon Angioplasty for Diffuse In-stent Restenosis (ROSTER). *Am Heart J*. 2004;147:16-22.
105. Kobayashi Y, Teirstein P, Linnemeier T, Stone G, Leon M, Moses J. Rotational atherectomy (stentablation) in a lesion with stent underexpansion due to heavily calcified plaque. *Catheter Cardiovasc Interv*. 2001;52:208-11.
106. Alfonso F, Sandoval J, Nolte C. Calcified in-stent restenosis: a rare cause of dilation failure requiring rotational atherectomy. *Circ Cardiovasc Interv*. 2012;5:e1-2.
107. Hill JM, Kerieakes DJ, Shlofmitz RA, Klein AJ, Riley RF, Price MJ, Herrmann HC, Bachinsky W, Waksman R, Stone GW; Disrupt CAD III Investigators. Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Artery Disease. *J Am Coll Cardiol*. 2020;76:2635-46.
108. Kerieakes DJ, Di Mario C, Riley RF, Fajadet J, Shlofmitz RA, Saito S, Ali ZA, Klein AJ, Price MJ, Hill JM, Stone GW. Intravascular Lithotripsy for Treatment of Calcified Coronary Lesions: Patient-Level Pooled Analysis of the Disrupt CAD Studies. *JACC Cardiovasc Interv*. 2021;14:1337-48.
109. Nikolakopoulos I, Vemmo E, Xenogiannis I, Brilakis ES. Combined use of intravascular lithotripsy and brachytherapy: A new approach for the treatment of recurrent coronary in-stent restenosis. *Catheter Cardiovasc Interv*. 2021;97:1402-6.
110. Salazar C, Escaned J, Tirado G, Gonzalo N. Intravascular lithotripsy for recurrent restenosis caused by severe calcific neoatherosclerosis. *EuroIntervention*. 2020;16:e351-2.
111. Tizón-Marcos H, Rodríguez-Costoya I, Tevar C, Vaquerizo B. Intracoronary lithotripsy for calcific neoatherosclerotic in-stent restenosis: a case report. *Eur Hear J Case Rep*. 2020;4:1-4.
112. Brunner FJ, Becher PM, Waldeyer C, Zengin-Sahm E, Schnabel RB, Clemmensen P, Westermann D, Blankenberg S, Seiffert M. Intravascular Lithotripsy for the Treatment of Calcium-Mediated Coronary In-Stent Restenoses. *J Invasive Cardiol*. 2021;33:E25-31.
113. Alfonso F, Bastante T, Antuña P, de la Cuerda F, Cuesta J, García-Guimaraes M, Rivero F. Coronary Lithoplasty for the Treatment of Undilatable Calcified De Novo and In-Stent Restenosis Lesions. *JACC Cardiovasc Interv*. 2019;12:497-9.
114. Mintz GS, Hoffmann R, Mehran R, Pichard AD, Kent KM, Satler LF, Popma JJ, Leon MB. In-stent restenosis: the Washington Hospital Center experience. *Am J Cardiol*. 1998;81:7E-13E.
115. Alfonso F, Zueco J, Cequier A, Mantilla R, Bethencourt A, López-Mínguez JR, Angel J, Augé JM, Gómez-Recio M, Moris C, Seabra-Gomes R, Perez-Vizcayno MJ, Macaya C; Restenosis Intra-stent: Balloon Angioplasty Versus Elective Stenting (RIBS) Investigators. A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. *J Am Coll Cardiol*. 2003;42:796-805.
116. Alfonso F, Melgares R, Mainar V, Lezaún R, Vázquez N, Tascón J, Pomar F, Cequier A, Angel J, Pérez-Vizcayno MJ, Sabatè M, Bañuelos C, Fernández C, García JM; Restenosis Intra-stent: Balloon angioplasty versus elective Stenting (RIBS) Investigators. Therapeutic implications of in-stent restenosis located at the stent edge. Insights from the restenosis intra-stent balloon angioplasty versus elective stenting (RIBS) randomized trial. *Eur Heart J*. 2004;25:1829-35.
117. Alfonso F, Cuesta J, Pérez-Vizcayno MJ, García del Blanco B, Rumoroso JR, Bosa F, Pérez de Prado A, Masotti M, Moreno R, Cequier A, Gutiérrez H, García Touchard A, López-Mínguez JR, Zueco J, Martí V, Velázquez M, Moris C, Bastante T, García-Guimaraes M, Rivero F, Fernández C; Interventional Cardiology Working Group of the Spanish Society of Cardiology. Bioresorbable Vascular Scaffolds for Patients With In-Stent Restenosis: The RIBS VI Study. *JACC Cardiovasc Interv*. 2017;10:1841-51.
118. Alfonso F, Cuesta J, García Del Blanco B, Bosa F, Pérez de Prado A, Masotti M, Trillo R, Rumoroso JR, Moreno R, Cequier A, Gutiérrez H, García Touchard A, López-Mínguez JR, Zueco J, Serra A, Velázquez M, Moris C, Bastante T, García-Guimaraes M, Rivero F, Fernández-Pérez C; Restenosis Intra-stent: Bioresorbable Vascular Scaffolds Treatment with Scoring Balloon Pre-dilatation (RIBS VI 'Scoring') Study Investigators (under the auspices of the Interventional Cardiology Working Group of the Spanish Society of Cardiology). Scoring balloon predilatation before bioresorbable vascular scaffold implantation in patients with in-stent restenosis: the RIBS VI 'scoring' study. *Coron Artery Dis*. 2021;32:96-104.
119. Ali ZA, Serruys PW, Kimura T, Gao R, Ellis SG, Kerieakes DJ, Onuma Y, Simonton C, Zhang Z, Stone GW. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. *Lancet*. 2017;390:760-72.
120. Alfonso F, Cuesta J, García-Guimaraes M, Bastante T, Maruri R, Rivero F. Treatment of coronary stent restenosis with drug-eluting bioabsorbable magnesium scaffolds. *Coron Artery Dis*. 2017;28:627-8.
121. Alfonso F, Cuesta J, García-Guimaraes M and Rivero F. "Bumpy" neointima: the fingerprint of bioabsorbable magnesium scaffold resorption. *EuroIntervention*. 2019;15:e380-1.
122. Alfonso F, Cuesta J, Ojeda S, Camacho-Freire S, García Del Blanco B, Vaquerizo B, Zueco J, Trillo R, Mauri J, Velázquez M, Córdoba-Soriano JG, Serra A, Navarro F, Pan M, Díaz J, Otaegui I, Salvatella N, De la Torre-Hernandez JM, Val DD, Bastante T, Rivero F; Under the auspices of the Association of Interventional Cardiology of the Spanish Society of Cardiology. Procedural Results and One-Year Clinical Outcomes of Treatment of Bioresorbable Vascular Scaffolds Restenosis (from the RIBS VII Prospective Study). *Am J Cardiol*. 2022;162:31-40.
123. Moustapha A, Assali AR, Sdringola S, Vaughn WK, Fish RD, Rosales O, Schroth G, Krajcer Z, Smalling RW, Anderson HV. Percutaneous and surgical interventions for in-stent restenosis: long-term outcomes and effect of diabetes mellitus. *J Am Coll Cardiol*. 2001;37:1877-82.
124. Kanemitsu S, Tanaka K, Tanaka J, Suzuki H, Kinoshita T. Coronary artery bypass grafting following in-stent restenosis of drug-eluting stents deployed in the left main coronary artery. *Circ J*. 2008;72:502-4.
125. Hausleiter J, Kastrati A, Mehilli J, Vogeser M, Zohlnhöfer D, Schühlen H, Goos C, Pache J, Dotzer F, Pogatsa-Murray G, Dirschinger J, Heemann U, Schömig A; OSIRIS Investigators. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. *Circulation*. 2004;110:790-5.
126. Kufner S, Hausleiter J, Ndrepepa G, Schulz S, Bruskina O, Byrne RA, Fusaro M, Kastrati A, Schömig A, Mehilli J; OSIRIS Trial Investigators. Long-term risk of adverse outcomes and new malignancies in patients treated with oral sirolimus for prevention of restenosis. *JACC Cardiovasc Interv*. 2009;2:1142-8.

127. Yabushita H, Kawamoto H, Fujino Y, Tahara S, Horikoshi T, Tada M, Amano T, Onishi H, Nakajima A, Warisawa T, Watanabe Y, Yoshizaki T, Mitomo S, Sato T, Naganuma T, Ishiguro H, Kurita N, Nakamura S, Hozawa K, Nakamura S. Clinical Outcomes of Drug-Eluting Balloon for In-Stent Restenosis Based on the Number of Metallic Layers. *Circ Cardiovasc Interv*. 2018;11:e005935.
128. Alfonso F, García J, Pérez-Vizcayno MJ, Hernando L, Hernandez R, Escaned J, Jiménez-Quevedo P, Bañuelos C, Macaya C. New stent implantation for recurrences after stenting for in-stent restenosis: implications of a third metal layer in human coronary arteries. *J Am Coll Cardiol*. 2009;54:1036-8.
129. Kubo S, Kadota K, Otsuru S, Hasegawa D, Shigemoto Y, Habara S, Tada T, Tanaka H, Fuku Y, Katoh H, Goto T, Mitsudo K. Optimal treatment of recurrent restenosis lesions after drug-eluting stent implantation for in-stent restenosis lesions. *EuroIntervention*. 2013;9:788-96.
130. Kan J, Ge Z, Zhang JJ, Liu ZZ, Tian NL, Ye F, Li SJ, Qian XS, Yang S, Chen MX, Rab T, Chen SL. Incidence and Clinical Outcomes of Stent Fractures on the Basis of 6,555 Patients and 16,482 Drug-Eluting Stents From 4 Centers. *JACC Cardiovasc Interv*. 2016;9:1115-23.
131. Raja Y, Routledge HC, Doshi SN. A noncompliant, high pressure balloon to manage undilatable coronary lesions. *Catheter Cardiovasc Interv*. 2010;75:1067-73.
132. D'Ascenzo F, Chieffo A, Cerrato E, Ugo F, Pavani M, Kawamoto H, di Summa R, Varbella F, Boccuzzi G, Omedè P, Rettegno S, Garbo R, Conrotto F, Montefusco A, Biondi-Zoccai G, D'Amico M, Moretti C, Escaned J, Gaita F, Colombo A. Incidence and Management of Restenosis After Treatment of Unprotected Left Main Disease With Second-Generation Drug-Eluting Stents (from Failure in Left Main Study With 2nd Generation Stents-Cardiogram III Study). *Am J Cardiol*. 2017;119:978-82.
133. Sheiban I, Sillano D, Biondi-Zoccai G, Chieffo A, Colombo A, Vecchio S, Margheri M, Gunn JP, Raina T, Liistro F, Bolognese L, Lee MS, Tobis J, Moretti C. Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents 70 restenotic cases from a cohort of 718 patients: FAILS (Failure in Left Main Study). *J Am Coll Cardiol*. 2009;54:1131-6.
134. Kook H, Joo HJ, Park JH, Hong SJ, Yu CW, Lim DS. A comparison between drug-eluting stent implantation and drug-coated balloon angioplasty in patients with left main bifurcation in-stent restenotic lesions. *BMC Cardiovasc Disord*. 2020;20:83.
135. Wiebe J, Kuna C, Ibrahim T, Lösl M, Cassese S, Kufner S, Schunkert H, Byrne RA, Laugwitz KL, Valgimigli M, Richardt G, Mehilli J, Kastrati A. Long-Term Prognostic Impact of Restenosis of the Unprotected Left Main Coronary Artery Requiring Repeat Revascularization. *JACC Cardiovasc Interv*. 2020;13:2266-74.
136. Abdel-Karim AR, Lombardi WB, Banerjee S, Brilakis ES. Contemporary outcomes of percutaneous intervention in chronic total coronary occlusions due to in-stent restenosis. *Cardiovasc Revasc Med*. 2011;12:170-6.
137. Lee SH, Cho JY, Kim JS, Lee HJ, Yang JH, Park JH, Hong SJ, Choi RK, Choi SH, Gwon HC, Lim DS, Yu CW. A comparison of procedural success rate and long-term clinical outcomes between in-stent restenosis chronic total occlusion and de novo chronic total occlusion using multicenter registry data. *Clin Res Cardiol*. 2020;109:628-37.
138. Christopoulos G, Karpaliotis D, Alaswad K, Lombardi WL, Grantham JA, Rangan BV, Kotsia AP, Lembo N, Kandzari DE, Lee J, Kalynych A, Carlson H, Garcia S, Banerjee S, Thompson CA, Brilakis ES. The efficacy of "hybrid" percutaneous coronary intervention in chronic total occlusions caused by in-stent restenosis: insights from a US multicenter registry. *Catheter Cardiovasc Interv*. 2014;84:646-51.
139. de la Torre Hernandez JM, Rumoroso JR, Subinas A, Gonzalo N, Ojeda S, Pan M, Martín Yuste V, Suárez A, Hernández F, Teruel L, Moreu J, Cubero JM, Cascón JD, Vinhas H, Lozano Í, Martín Moreiras J, Pérez de Prado A, Goicolea J, Escaned J. Percutaneous intervention in chronic total coronary occlusions caused by in-stent restenosis: procedural results and long-term clinical outcomes in the TORO (Spanish registry of chronic Total occlusion secondary to an occlusive in-stent Restenosis) multicentre registry. *EuroIntervention*. 2017;13:e219-26.
140. Vemou E, Quadros AS, Dens JA, Rafèh NA, Agostoni P, Alaswad K, Avran A, Belli KC, Carlino M, Choi JW, El-Guindy A, Jaffer FA, Karpaliotis D, Khatri JJ, Khelmskii D, Knaapen P, La Manna A, Krestyaninov O, Lamelas P, Ojeda S, Padilla L, Pan M, Piccaro de Oliveira P, Pinfret S, Spratt JC, Tanabe M, Walsh S, Nikolakopoulos I, Karacsonyi J, Rangan BV, Brilakis ES, Azzalini L. In-Stent CTO Percutaneous Coronary Intervention: Individual Patient Data Pooled Analysis of 4 Multicenter Registries. *JACC Cardiovasc Interv*. 2021;14:1308-19.
141. Lemos PA, Saia F, Ligthart JMR, Arampatzis CA, Sianos G, Tanabe K, Hoye A, Degertekin M, Daemen J, McFadden E, Hofma S, Smits PC, de Feyter P, van der Giessen WJ, van Domburg RT, Serruys PW. Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. *Circulation*. 2003;108:257-60.
142. Sianos G, Hofma S, Ligthart JM, Saia F, Hoye A, Lemos PA, Serruys PW. Stent fracture and restenosis in the drug-eluting stent era. *Catheter Cardiovasc Interv*. 2004;61:111-6.
143. Kim JS, Lee SY, Lee JM, Yoon YW, Ahn CM, Kim MH, Min PK, Ko YG, Hong BK, Choi D, Kwon HM, Jang Y, Shim WH. Significant association of coronary stent fracture with in-stent restenosis in sirolimus-eluting stents. *Coron Artery Dis*. 2009;20:59-63.
144. Stefanini GG, Alfonso F, Barbato E, Byrne RA, Capodanno D, Colleran R, Escaned J, Giacoppo D, Kunadian V, Lansky A, Mehilli J, Neumann FJ, Regazzoli D, Sanz-Sanchez J, Wijns W, Baumbach A. Management of myocardial revascularisation failure: an expert consensus document of the EAPCI. *EuroIntervention*. 2020;16:e875-90.
145. Jeger RV, Eccleshall S, Wan Ahmad WA, Ge J, Poerner TC, Shin ES, Alfonso F, Latib A, Ong PJ, Rissanen TT, Saucedo J, Scheller B, Kleber FX; International DCB Consensus Group. Drug-Coated Balloons for Coronary Artery Disease: Third Report of the International DCB Consensus Group. *JACC Cardiovasc Interv*. 2020;13:1391-402.
146. Xhepa E, Bresha J, Joner M, Hapfelmeier A, Rivero F, Ndrepepa G, Nano N, Cuesta J, Kufner S, Cassese S, Bastante T, Aytakin A, Rroku A, García-Guimaraes M, Lahmann AL, Piniack S, Rai H, Fusaro M, Schunkert H, Pérez-Vizcayno MJ, Gonzalo N, Alfonso F, Kastrati A. Clinical outcomes by optical characteristics of neointima and treatment modality in patients with coronary in-stent restenosis. *EuroIntervention*. 2021;17:e388-95.
147. Alfonso F, Augé JM, Zueco J, Bethencourt A, López-Mínguez JR, Hernández JM, Bullones JA, Calvo I, Esplugas E, Pérez-Vizcayno MJ, Moreno R, Fernández C, Hernández R, Gama-Ribeiro V; RIBS Investigators. Long-Term results (three to five years) of the Restenosis Intra-stent: Balloon angioplasty versus elective stenting (RIBS) randomized study. *J Am Coll Cardiol*. 2005;46:756-60.
148. Tamez H, Secemsky EA, Valsdottir LR, Moussa ID, Song Y, Simonton CA, Gibson CM, Popma JJ, Yeh RW. Long-term outcomes of percutaneous coronary intervention for in-stent restenosis among Medicare beneficiaries. *EuroIntervention*. 2021;17:e380-7.
149. Campo G, Tebaldi M, Vranckx P, Biscaglia S, Tumscitz C, Ferrari R, Valgimigli M. Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia). *J Am Coll Cardiol*. 2014;63:506-12.
150. Waksman R, Bhargava B, White L, Chan RC, Mehran R, Lansky AJ, Mintz GS, Satler LF, Pichard AD, Leon MB, Kent KK. Intracoronary beta-radiation therapy inhibits recurrence of in-stent restenosis. *Circulation*. 2000;101:1895-8.
151. Ragosta M, Samady H, Gimple LW, Sarembock IJ, Fenster M, Powers ER. Percutaneous treatment of focal vs. diffuse in-stent restenosis: a prospective randomized comparison of conventional therapies. *Catheter Cardiovasc Interv*. 2004;61:344-9.
152. Montorsi P, Galli S, Fabbiochi F, Trabattini D, Ravagnani PM, Bartorelli AL. Randomized trial of conventional balloon angioplasty versus cutting balloon for in-stent restenosis. Acute and 24-hour angiographic and intravascular ultrasound changes and long-term follow-up. *Ital Heart J*. 2004;5:271-9.
153. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. *N Engl J Med*. 2006;355:2113-24.
154. Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C, Werner GS, Antoni D, Kleber FX, Bocksch W, Leschke M, Ackermann H, Boxberger M, Speck U, Degenhardt R, Scheller B. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. *Circulation*. 2009;119:2986-94.
155. Wiemer M, König A, Rieber J, Sohn HY, Leibig M, Theisen K, Klaus V, Langer C, Lindner O, Horstkotte D, Schiele TM. Sirolimus-eluting stent implantation versus beta-irradiation for the treatment of in-stent restenotic lesions: clinical and ultrasound results from a randomized trial. *EuroIntervention*. 2011;6:687-94.
156. Song HG, Park DW, Kim YH, Ahn JM, Kim WJ, Lee JY, Kang SJ, Lee SW, Lee CW, Park SW, Han S, Seong IW, Lee NH, Lee BK, Lee K, Lee SW, Nah DY, Park SJ. Randomized trial of optimal treatment strategies for in-stent restenosis after drug-eluting stent implantation. *J Am Coll Cardiol*. 2012;59:1093-100.
157. Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, García Del Blanco B, Seidelberger B, Iñiguez A, Gómez-Reico M, Masotti M, Velázquez MT, Sanchis J, García-Touchard A, Zueco J, Bethencourt A, Melgares R, Cequier A, Dominguez A, Mainar V, López-Mínguez JR, Moreu J, Martí V, Moreno R, Jiménez-Quevedo P, Gonzalo N, Fernández C, Macaya C; RIBS V Study Investigators, under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). *J Am Coll Cardiol*. 2014;63:1378-86.
158. Xu B, Gao R, Wang J, Yang Y, Chen S, Liu B, Chen F, Li Z, Han Y, Fu G, Zhao Y, Ge J; PEPCAD China ISR Trial Investigators. A prospective, multicenter, randomized

trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial. *JACC Cardiovasc Interv.* 2014;7:204-11.

159. Adriaenssens T, Dens J, Ughi G, Bennett J, Dubois C, Sinnaeve P, Wiyono S, Coosemans M, Belmans A, D'Hooge J, Vrolix M, Desmet W. Optical coherence tomography study of healing characteristics of paclitaxel-eluting balloons vs. everolimus-eluting stents for in-stent restenosis: the SEDUCE (Safety and Efficacy of a Drug eluting balloon in Coronary artery rEstenosis) randomised clinical trial. *EuroIntervention.* 2014;10:439-48.

160. Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, García del Blanco B, García-Touchard A, López-Minguéz JR, Benedicto A, Masotti M, Zueco J, Iñiguez A, Velázquez M, Moreno R, Mainar V, Domínguez A, Pomar F, Melgares R, Rivero F, Jiménez-Quevedo P, Gonzalo N, Fernández C, Macaya C. A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents: The RIBS IV Randomized Clinical Trial. *J Am Coll Cardiol.* 2015;66:23-33.

161. Pleva L, Kukla P, Kusnierova P, Zapletalova J, Hlinomaz O. Comparison of the Efficacy of Paclitaxel-Eluting Balloon Catheters and Everolimus-Eluting Stents in the Treatment of Coronary In-Stent Restenosis: The Treatment of In-Stent Restenosis Study. *Circ Cardiovasc Interv.* 2016;9:e003316.

162. Hong SJ, Ahn CM, Kim BK, Ko YG, Hur SH, Yu CW, Lee SJ, Choi CU, Kim JS, Yoon JH, Hong YJ, Choi JW, Choi SH, Jang Y, Lim DS; RESTENT-ISR Investigators. Prospective randomized comparison of clinical and angiographic outcomes between everolimus-eluting vs. zotarolimus-eluting stents for treatment of coronary restenosis in drug-eluting stents: intravascular ultrasound volumetric analysis (RESTENT-ISR trial). *Eur Heart J.* 2016;37:3409-18.

163. Baan J Jr, Claessen BE, Dijk KB, Vendrik J, van der Schaaf RJ, Meuwissen M, van Royen N, Gosselink ATM, van Wely MH, Dirkali A, Arkenbout EK, de Winter RJ, Koch KT, Sjaauw KD, Beijik MA, Vis MM, Wykrzykowska JJ, Piek JJ, Tijssen JGP,

Henriques JPS. A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the Treatment of Any In-Stent Restenosis: The DARE Trial. *JACC Cardiovasc Interv.* 2018;11:275-83.

164. Wong YTA, Kang DY, Lee JB, Rha SW, Hong YJ, Shin ES, Her SH, Nam CW, Chung WY, Kim MH, Lee CH, Lee PH, Ahn JM, Kang SJ, Lee SW, Kim YH, Lee CW, Park SW, Park DW, Park SJ. Comparison of drug-eluting stents and drug-coated balloon for the treatment of drug-eluting coronary stent restenosis: A randomized RESTORE trial. *Am Heart J.* 2018;197:35-42.

165. Jensen CJ, Richardt G, Tölg R, Erglis A, Skurk C, Jung W, Neumann FJ, Stangl K, Brachmann J, Fischer D, Mehilli J, Rieber J, Wiemer M, Schofer J, Sack S, Naber CK. Angiographic and clinical performance of a paclitaxel-coated balloon compared to a second-generation sirolimus-eluting stent in patients with in-stent restenosis: the BIOLUX randomised controlled trial. *EuroIntervention.* 2018;14:1096-103.

Supplementary data

Supplementary Appendix 1. Search strategy for systematic review.

Supplementary Table 1. Randomised controlled trials on the treatment of in-stent restenosis: trial characteristics.

Supplementary Table 2. Randomised controlled trials on the treatment of in-stent restenosis: angiographic and clinical endpoints.

The supplementary data are published online at:

<https://eurointervention.pcronline.com/>

doi/10.4244/EIJ-D-21-01034



Supplementary data

Supplementary Appendix 1. Search strategy for systematic review.

PubMed

((Coronary[Title/Abstract]) AND (In-Stent[Title/Abstract])) AND (Restenosis[Title/Abstract])

Scopus

TITLE-ABS-KEY (coronary) AND TITLE-ABS-KEY (in-stent) AND TITLE-ABS-KEY (restenosis) AND (LIMIT-TO (DOCTYPE , "ar") OR LIMIT-TO (DOCTYPE , "le")) AND (LIMIT-TO (SUBJAREA , "MEDI")) AND (LIMIT-TO (SRCTYPE , "j") OR LIMIT-TO (SRCTYPE , "p"))

Web of Science

((TS=(Coronary)) OR TI=(Coronary)) OR AB=(Coronary)

((TS=(In-Stent)) OR TI=(In-Stent)) OR AB=(In-Stent)

((TS=(Restenosis)) OR TI=(Restenosis)) OR AB=(Restenosis)

#1 AND #2 AND #3

Document Type: Articles or Proceedings Paper or Meeting Abstracts

Ovid

(Coronary and In-Stent and Restenosis).ti,ab,kw.

1 and "Clinical Trial" [Publication Type]

1 and "Randomised Controlled Trial" [Publication Type]

1 and "Comparative Study" [Publication Type]

1 and "Clinical Study" [Publication Type]

1 and "Controlled Clinical Trial" [Publication Type]

2 or 3 or 4 or 5

Supplementary Table 1. Randomised Controlled Trials on the treatment of in-stent restenosis: Trial Characteristics

Trial Characteristics					Baseline Characteristics				
First Author/Trial (Ref. #)	Year	Stent	Therapy	n	Age (years)	DM (%)	Length (mm)	RVD (mm)	MLD (mm)
Teirstein et al. (95)	1997	BMS	IVBT	26	70	27.0	12.9	2.88	1.10
			BA/BMS	29	69	41.0	11.9	2.78	1.03
WRIST (150)	2000	BMS	IVBT	65	63	39.0	28.8	2.71	0.94
			PCI	65	62	45.0	26.7	2.72	0.81
GAMMA-ONE (94)	2001	BMS	IVBT	131	58	31.0	19.0	2.69	0.98
			PCI	121	61	31.0	20.3	2.73	0.96
ARTIST (103)	2002	BMS	BA	146	61	25.0	13.6	2.65	0.53
			RA	152	62	26.0	13.6	2.63	0.54
RESCUT (88)	2003	BMS	CB	214	62	24.0		2.58	0.83
			BA	214	61	27.0		2.53	0.84
RIBS I (115)	2003	BMS	BMS	224	61	27.0	12.7	2.87	0.68
			BA	226	61	26.0	13.0	2.83	0.67
Long WRIST (93)	2003	BMS	PCI	60	61	37.0	29.1	2.55	0.70
			IVBT	60	63	42.0	29.2	2.57	0.80
OSIRIS (125)	2004	BMS	BA	102	65	27.5		2.61	
			SIR	99	65	27.3		2.60	
			SIRhd	99	65	32.2		2.57	
Ragosta et al. (151)	2004	BMS	BA	29	63	21.0	5.1	3.02	0.79
			BMS	29	64	10.0	7.3	3.12	0.85
			RA	30	59	47.0	20.6	2.81	0.69

			BMS	25	59	32.0	18.2	2.99	0.79
Montorsi et al. (152)	2004	BMS	BA	25	61			3.19	1.07
			CB	25	66			3.28	0.93
ROSTER (104)	2004	BMS	RA	100	63	31.0	18.6	2.85	0.82
			BA/BMS	100	65	30.0	16.7	2.82	0.92
Alfonso et al. (86)	2005	BMS	BMS	20	66	40.0	12.8	2.55	0.91
			BA	20	66	30.0	12.0	2.55	1.00
ISAR-DESIRE (42)	2005	BMS	DES-S	100	63	31.0	12.4	2.60	0.91
			DES-P	100	65	27.0	11.5	2.60	0.97
			BA	100	64	25.0	12.3	2.57	0.95
PACCOCATH-ISR (153)	2006	BMS	DCB	26	64	15.0	17.9	2.94	0.75
			BA	26	64	15.0	18.1	2.95	0.67
RIBS II (57)	2006	BMS	DES	76	64	38.0	16.9	2.66	0.74
			BA	74	64	31.0	15.7	2.68	0.70
SISR (59)	2006	DES-BMS	DES	259	63	33.3	17.2	2.62	0.78
			IVBT	125	64	29.6	16.8	2.64	0.86
TAXUS V ISR (60)	2006	BMS	IVBT	201	63	30.3	15.0	2.61	0.83
			DES-P	195	63	40.0	15.9	2.68	0.80
INDEED (61)	2007	BMS	DES	65	61	30.8	27.5	2.77	0.78
			IVBT	64	60	31.3	27.8	2.67	0.81
PEPCAD II (154)	2009	DES-BMS	DCB	66	65	33.3	15.7	2.85	0.74
			DES	65	65	26.2	15.4	2.83	0.77
ISAR-DESIRE 2 (43)	2010	DES	DES-P	225	67	38.8	12.5	2.75	0.95
			DES-S	225	66	38.2	12.7	2.78	1.02
Habara et al. (66)	2011	DES	DCB	25	70	56.0	12.7	2.69	0.99
			BA	25	69	68.0	13.2	2.90	0.92

Wiemer et al. (155)	2011		DES	44	65	49.0	25.2	2.89	0.70
			IVBT	47	64	49.0	17.2	2.77	0.85
PEPCAD- DES (69)	2012	DES	DCB	72	70	36.1	11.2	2.29	0.66
			BA	38	64	34.2	12.2	2.30	0.62
Song et al. (156)	2012	DES	CB	48	62	31.2	7.5	2.93	0.80
			DES-S	48	65	37.5	8.6	3.18	0.68
			S-DES-d	32	61	25.0	22.2	3.19	0.94
			E-DES-d	34	65	35.3	22.5	3.43	0.75
CRISTAL (58)	2012	DES	DES-S	136	68	39.0	14.6	2.60	1.09
			BA	61	67	38.0	13.4	2.50	1.58
ISAR-DESIRE 3 (44)	2013	DES	DCB	137	68	41.0		2.75	0.97
			DES-P	131	69	47.0		2.80	0.93
			BA	134	67	37.0		2.72	0.88
Habara et al. (70)	2013	DES/BMS	DCB	137	68	46.0	12.8	2.52	0.86
			BA	71	70	42.0	13.7	2.49	0.84
RIBS V (157)	2014	BMS	DCB	95	67	32.0	13.7	2.64	1.02
			DES-E	94	64	20.0	13.8	2.64	0.93
PEPCAD-CHINA ISR (158)	2014	DES	DCB	109	62	40.0	12.5	2.66	0.85
			DES-P	106	62	33.0	13.8	2.72	0.86
SEDUCE (159)	2014	BMS	DCB	25	68	24.0		3.00	0.98
			DES-E	25	64	4.0		2.85	0.57
RIBS IV (160)	2015	DES	DCB	154	66	49	10.4	2.59	0.79
			DES-E	155	66	43	10.7	2.67	0.75
PATENT-C (81)	2015	BMS	Standard Scoring Balloon	28	64	35.7	13.8	2.54	0.73
			Paclitaxel Coated Scoring Balloon	33	65	42.4	16.5	2.72	0.90

TIS (161)	2016	BMS	DCB	68	65.6	25.0	22.5	2.64	0.92
			DES-E	68	65.5	26.5	28.5	2.66	0.79
RESTENT- ISR (162)	2016	DES	DES-E	158	64.1	36.7	22.5	3.07	0.78
			DES-Z	146	62.2	36.3	24.7	3.15	0.89
ISAR-DESIRE 4 (80)	2017	DES	Scoring Balloon pre DCB	125	69.4	40.8		2.96	1.01
			Standard Treatment pre DCB	127	69.4	43.3		2.89	0.94
DARE (163)	2017	DES-BMS	DCB	137	66	42		2.56	0.77
			DES-E	141	65	46		2.59	0.79
RESTORE (164)	2017	DES	DCB	86	67	50.0	18.1	2.85	0.63
			DES-E	86	66	44.2	17.4	3.06	0.63
BIOLUX-RCT (165)	2018	DES-BMS	DCB	157	67.2	30.6	5.8	3.0	1.0
			DES	72	69.4	33.3	7.2	2.9	0.9
RESTORE ISR CHINA (67)	2018	DES	RESTORE DCB	120	63.6	38.3	16.5	2.79	0.91
			SEQUENT PLEASE DCB	120	63.9	38.3	16.2	2.71	0.90
Ali et al. (79)	2019	DES	PACLITAXEL DCB	25	58.6	76	13.3	2.42	0.80
			SIROLIMUS DCB	25	61.6	72	14.2	2.53	0.81
ELEGANT (91)	2019	DES-BMS	NON-SLIP BALLOON PRE DCB	105	70.0	51.4	13.8	2.56	0.93
			HPNCB PRE DCB	105	68.9	47.6	13.3	2.54	0.91
Sato et al. (102)	2019	DES-BMS	ELCA + DCB	20	69.0	50.0	13.9	2.75	0.67
			DCB	20	69.1	75.0	15.5	2.83	1.00

AGENT ISR (68)	2019	DES-BMS	Agent DCB	65	68	36.9	11.7	2.60	0.75
			SeQuent DCB	60	69	36.7	13.3	2.48	0.65

Supplementary Table 2. Randomised Controlled Trials on the treatment of in-stent restenosis: Angiographic and Clinical Endpoints

Trial Characteristics				Angiographic Endpoints						Clinical Endpoints				
First Author/Trial (Ref. #)	Year	Therapy	Time (months)	RE (%)	ISTLL (mm)	ISGLL (mm)	MLD (mm)	DS (%)	Time (months)	MACE (%)	Death (%)	MI (%)	TLR (%)	TVR (%)
Teirstein et al. (95)	1997	IVBT	6	17*	0.38*		2.43*	17.0*	12	15.0*	0.0	4.0	12.0*	
		BA/BMS		54	1.03		1.85	37.0		48.0	3.0	0.0	45.0	
WRIST (150)	2000	IVBT	6	22*	0.22*		2.03*	30.0*	12	35.3*	6.2	9.2	23.0*	33.8*
		PCI		60	1.00		1.24	57.0		67.3	6.2	9.2	63.1	67.6
GAMMA-ONE (94)	2001	IVBT	6	32*	0.73*		1.78*	46.0*	9	28.2*	3.1	9.9	24.4*	31.3*
		PCI		55	1.14		1.37	53.0		43.8	0.8	4.1	42.1	46.3
ARTIST (103)	2002	BA	6	51*	0.67*		1.20*	56.0*	6	20.4			31.0	
		RA		64	0.91		0.99	63.0		9.9*			39.0	
RESCUT (88)	2003	CB	7	30	0.56		1.61	39.0	7	16.4	1.4	1.4	13.5	
		BA		31	0.62		1.55	40.0		15.4	0.9	1.4	13.1	
RIBS I (115)	2003	BMS	6	38	1.12	1.06	1.63	45.0	12	23.0	4.0	2.2		19.6
		BA		39	0.73*	0.72	1.52	46.0		29.0	3.0	5.3		24.3
Long WRIST (93)	2003	PCI	4-8	73	0.99	0.85	0.93	65.0	12	63.3	1.7	18.3	61.7	
		IVBT		45*	0.67*	0.65*	1.23	54.0*		42.2*	6.8	23.7	39.0*	
OSIRIS (125)	2004	BA	6	42	0.60		1.53	43.7	12	27.5	0.0	1.0		25.5
		SIR		39	0.72		1.37	45.8		29.3	3.0	0.0		24.2
		SIRhd		22*	0.49*		1.66*	38.1		18.2	2.0	0.0		15.2
Ragosta et al. (151)	2004	BA							9	21.0	0.0	7.2		17.0
		BMS						7.0		3.6	3.6		3.6	
		RA						43.0		6.6	3.3		40.0	
		BMS						32.0		0.0	4.0		32.0	
Montorsi et al. (152)	2004	BA							6	28.0	0.0		40.0	
		CB						17.0		0.0		12.5*		
ROSTER (104)	2004	RA	9	42					12	38.0*	2.0	3.0	32.0	
		BA/BMS		56						52.0	2.0	3.0	45.0	
	2005	BMS							23	25.0	5.0	0.0		20.0

Alfonso et al. (86)		BA								50.0	15.0	10.0		35.0
ISAR-DESIRE (42)	2005	DES-S	6-8	14*	0.10	0.30	2.12	23.1	12	11.0	2.0	1.0		8.0
		DES-P		22*	0.26	0.55	2.02	26.6		22.0	1.0	2.0		19.0
		BA		45			1.40	45.8		36.0	3.0	0.0		33.0
PACCOCATH-ISR (153)	2006	DCB	6	5*	0.09*	0.03*	2.31		12	4.0*	4.0	4.0	0.0*	
		BA		43	0.76	0.74	1.60			31.0	0.0	8.0	23.0	
RIBS II (57)	2006	DES	9	11*		0.13	2.52	8.0	12	11.8*	3.9	2.6		10.5*
		BA		39		0.69	1.54	40.0		31.1	4.1	2.7		29.7
SISR (59)	2006	DES	6	20	0.33	0.23	1.80	32.35	9	10.0*	0.0	0.4	8.5*	10.8*
		IVBT		30	0.27	0.33	1.52	40.97		19.2	0.0	0.0	19.2	21.6
TAXUS V ISR (60)	2006	IVBT	9	31		0.27	1.55	31.2	9	20.1	0.5	4.6	20.1	23.7
		DES-P		15*	0.25	0.11*	1.99	14.5		11.5*	0.0	3.7	7.9 *	12.0 *
INDEED (61)	2007	DES	6	6*	0.15*	0.23	2.29	20.42	12	7.7	3.1	1.5	4.6*	
		IVBT		21	0.55	0.40	1.76	32.61		18.8	0.0	0.0	18.8	
PEPCAD II (154)	2009	DCB	6	4.0	0.19*	0.17*	2.08	29.4	12	7.6	1.5	0.0	6.3	
		DES		12.0	0.45	0.38	2.11	34.2		16.9	0.0	1.5	15.4	
ISAR-DESIRE 2 (43)	2010	DES-P	6-8	21.0	0.38	0.25	2.16	25.4	12	19.6	4.5	1.8	13.8	
		DES-S		19.0	0.40	0.26	2.14	26.6		20.4	3.4	2.7	14.3	
Habara et al. (66)	2011	DCB	6	9.0*	0.18*	0.17*	1.82	34.2	6	4.3*	0.0	0.0	4.3*	
		BA		63.0	0.72	0.72	1.28	58.0		41.7	0.0	0.0	41.7	
Wiemer et al. (155)	2011	DES	6	4.0*	0.09*		2.66	7.78	12	4.0	2.0	0.0	2.0	2.0
		IVBT		23.0	0.39		1.75	36.9		27.0	2.0	6.0	16.0	19.0
PEPCAD- DES (69)	2012	DCB	6	17.0	0.43	0.32	1.75	29.6	6	16.7*	1.4	0.0	15.3*	
		BA		58.0	1.03	0.99	1.10	51.1		50.0	10.5	2.6	36.8	
Song et al. (156)	2012	CB	9	21.0	0.30	0.25	2.08	16.5	12	6.3	0.0	0.0	6.3	6.3
		DES-S		3.0	0.02	0.06*	2.57	12.5		6.3	0.0	6.3	0.0	0.0
		S-DES-d		5.0	0.13	0.13	2.58	25		9.6	3.1	3.1	3.1	3.1
		E-DES-d		14.0	0.07*	0.07	2.71	18		8.8	2.9	2.9	5.8	5.8
CRISTAL (58)	2012	DES-S	12	11.0	0.37		2.14*	21.0*	12		2.2	2.9	5.9	2.2
		BA		14.0	0.41		1.71	29.8			1.6	1.6	13.1	0.0
	2013	DCB	6-8	27.0*	0.37		1.79	38		23.5	2.2	2.1	22.1	24.2

ISAR-DESIRE 3 (44)		DES-P		24.0*	0.34		1.82	37.4		19.3	4.6	2.4	13.5	16.6
		BA		57.0	0.70		1.26	54.1		46.2	5.3	1.5	43.5	45.1
Habara et al. (70)	2013	DCB	6	4.3*	0.11*	0.18*	1.87*	28.1*	6	6.6*	0.0	0.0	2.9*	6.6*
		BA		31.9	0.49	0.72	1.42	44.1		31.0	0.0	0.0	31.0	31.0
RIBS V (157)	2014	DCB	6	9.5		0.14	2.03	24	12	8.0	4.0	3.0	6.0	6.0
		DES-E		4.7		0.04	2.44*	13*		6.0	0.0	4.0	1.0	2.0
PEPCAD-CHINA ISR (158)	2014	DCB	9	18.6	0.54	0.46	1.80	29	12	16.5	0.0	3.7	14.7	16.5
		DES-P		23.8	0.62	0.55	1.76	31		16.0	2.0	6.6	10.4	16.0
SEDUCE (159)	2014	DCB	9	9.1	0.28	0.16	2.13	26.4	12		4.2	0	4.2	8.3
		DES-E		0.0	0.07	0.08	2.54*	11.4*			4	4	8	16.0
RIBS IV (160)	2015	DCB	9	19		0.30	1.80	30	12	18	1.9	3.0	13.0	16.2
		DES-E		11		0.18	2.03*	23*		10*	2.6	1.3	4.5*	8.4*
PATENT-C (81)	2015	Standard Scoring Balloon	6	40.7		0.48	1.39	46.8	6	32.1	Cardiac Death	TVMI	32.1	-
		Paclitaxel Coated Scoring Balloon		7.4*		0.17*	1.80*	33.7*		6.1*	Cardiac Death	TVMI	3.0*	-
TIS (161)	2016	DCB	12	8.7		0.09*	2.09	26.2	12	10.3	Cardiac Death	1.5	-	7.4
		DES-E		19.1*		0.44	2.07	30.9		19.1	Cardiac Death	1.5	-	16.2
RESENT- ISR (162)	2016	DES-E	9		0.40		2.54	16.7	36	10.1	0.6	1.9	14.5	
		DES-Z			0.45		2.53	17.4		9.6	2.1	2.7	21.2	
ISAR-DESIRE 4 (80)	2017	Scoring Balloon pre DCB	6-8	18.5*		0.31	1.95	35*	12	18.4	1.6	3.2	16.2	-
		Standard Treatment pre DCB		32.0		0.41	1.77*	40.4		23.3	1.7	1.6	21.8	-
DARE (163)	2017	DCB	6	18.1		0.17*	1.71	36.1	12	10.9	0.7	2.2	-	8.8
		DES-E		20.9		0.45	1.74	33.8		9.2	1.4	2.8	-	7.1
	2017	DCB	9	19.5	0.20	0.15	1.8*	34	12	7.0	0.0	1.2	5.8	5.8

RESTORE (164)		DES-E		5.6	0.27	0.19	2.09	26		4.7	0.0	3.5	1.2	1.2
BIOLUX-RCT (165)	2018	DCB	6		0.03	-0.02	2.2.	28.5	18	17.9	Cardiac Death	TVMI	-	13.5
		DES			0.20	0.13	2.2	23.7*		18.6	Cardiac Death	TVMI	-	11.6
RESTORE ISR CHINA (67)	2018	RESTORE DCB	9	24.6	0.48	0.39	1.64	38.9	12	13.3	0.0	2.5	13.3	23.3
		SEQUENT PLEASE DCB		18.8	0.42	0.35	1.71	34.5		12.6	0.0	3.4	11.8	12.6*
Ali et al. (79)	2019	PACLITAXEL DCB	6	-	0.37	0.31	1.99	19.9	12	16	0.0	-	16	-
		SIROLIMUS DCB		-	0.26	0.18	1.99	17.8		12	0.0	-	12	-
ELEGANT (91)	2019	NON-SLIP BALLOON PRE DCB	8	12.9	-	0.28	1.82	30.4	8	7.0	1.0	0.0	6.0	7.0
		HPNCB PRE DCB		15.2	-	0.27	1.71	33.1		9.7	3.9	1.9	7.8	9.7
Sato et al. (102)	2019	ELCA + DCB	12	20	-	-0.25	-	-	12	-	-	-	10.0	-
		DCB		20	-	-0.33	-	-		-	-	-	20.0	-
AGENT ISR (68)	2019	Agent DCB	6	13.7	0.397		1.62	20.7	12		3.1	4.6	7.7	9.2
		SeQuent DCB		22.4	0.393		1.51	20.2			1.7	3.3	10.0	11.7

Supplementary Table 1 and Supplementary Table 2 Legend

Details of the literature search are given in the Methods. The primary endpoint of each trial is highlighted in bold. * =p value <0.05.

ARTIST: Angioplasty Versus Rotational Atherectomy for Treatment of Diffuse In-Stent Restenosis Trial; AGENT ISR: Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis; BA: balloon angioplasty; IVBT: intravascular brachytherapy; BIOLUX: Clinical Performance of the Pantera LUX Paclitaxel Releasing Balloon Versus the Drug Eluting Orsiro Hybrid Stent System in Patients With In-stent Restenosis; CB: cutting balloon; CRISTAL: A Prospective, Randomised, Multi-Center Comparison of the CYPHER Select™ Sirolimus-Eluting Stent and Balloon Re-Angioplasty for Treatment of Patients With Intra-Des Restenosis; DARE: Drug Eluting bAlloon for In-stent REstenosis. Multi-center, Randomised Trial to Study the Effect of the SeQuent Please Drug-eluting Balloon Versus the XIENCE Prime Drug-eluting Stent for the Treatment of In-stent Restenosis; DCB: drug-coated balloon; DES: drug-eluting stent(s); DES-E: everolimus drug eluting stent(s); DES-P: paclitaxel drug-eluting stent(s); DES-S: sirolimus drug-eluting stent(s); DM: diabetes mellitus; E-DES-d: everolimus-eluting stent for diffuse restenosis; ELEGANT: Effect of Combination of Non-sLip Element Balloon (NSE) and druG-coated bAlloon (DCB) for In-steNT Restenosis Lesions; INDEED: Treatment of diffuse IN-stent restenosis with Drug-Eluting stents vs. intracoronary bEta-raDiation therapy; ISAR-DESIRE: Intracoronary Stenting or Angioplasty for Restenosis Reduction: Drug-Eluting Stents for In-Stent Restenosis; ISAR-DESIRE 2: Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2); ISAR-DESIRE 3: Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 3; ISTLL: in-stent late loss; ISGLL: in-segment late loss; LL: lesion length; Long WRIST: Washington Radiation for In-Stent Restenosis Trial for Long Lesions; MACE: major adverse cardiac events (including death or cardiac death, myocardial infarction [MI], and target lesion revascularisation [TLR] or target vessel revascularisation [TVR] as considered in each trial for the combined outcome measure); MLD: minimal lumen diameter; OSIRIS: Oral Sirolimus to Inhibit Recurrent In-stent Stenosis; PACCOATH-ISR: Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons; PATENT-C: Treatment of Coronary In-stent Restenosis by a Paclitaxel Coated

AngioSculpt Scoring Balloon; PCI: percutaneous coronary intervention (BA, rotational atherectomy [RA], excimer coronary laser atherectomy [ECLA] , BMS); PEPCAD: The Paclitaxel-Eluting PTCA-Balloon Catheter to Treat Small Vessel Coronary Artery Disease. A Pilot Study; PEPCAD II: The Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease to Treat In-Stent Restenoses: A Comparison to the Paclitaxel-Eluting Taxus™ Stent. A Pilot Study; PEPCAD-CHINA: A Multicenter, Randomized, Active Controlled Clinical Study to Evaluate the Safety and Efficacy of the Treatment of In-stent Restenosis Lesion by Paclitaxel-eluting PTCA- Balloon Catheter Versus Paclitaxel-eluting Stent; PEPCAD DES: Treatment of DES-In-Stent Restenosis With SeQuent® Please Paclitaxel Eluting PTCA Catheter; RA: rotational atherectomy; RE: binary restenosis; RESCUT: Restenosis Cutting Balloon Evaluation Trial; RESTENT ISR: Prospective, Single-blinded, Randomized Comparison of the Clinical and Angiographic Results With Intravascular Analysis of Everolimus-Eluting Versus Zotarolimus-Eluting stents for In-Stent Restenosis(ISR) Lesions: Volumetric Analysis With Intravascular Ultrasound (IVUS): Phase IV Multicenter Trial; RESTORE: Treatment of Drug-Eluting Stent REstenosis Using Drug-Eluting STents vs. Drug-COated Balloon for Preventing REcurrent In-Stent Restenosis; RESTORE CHINA: Compare the Efficacy and Safety of RESTORE DEB and SeQuent Please in Chinese Patient With Coronary In-stent Restenosis; RIBS I: Restenosis Intra-stent Balloon Angioplasty Versus Elective Stenting; RIBS II: Restenosis Intra-stent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting; RIBS V: Restenosis Intra-stent: Drug-eluting Balloon vs. Everolimus-eluting Stent; ROSTER: Randomized Trial of Rotational Atherectomy Versus Balloon Angioplasty for Diffuse In-Stent Restenosis; RVD: reference vessel diameter; S-DES-d: sirolimus-eluting stent for diffuse restenosis; SEDUCE: Safety and Efficacy of a Drug eluting balloon in Coronary artery rEstenosis; SIR: usual dose oral sirolimus; SIRhd: high-dose oral sirolimus; SISR: Sirolimus-Eluting Stent vs. Brachytherapy in Patients With Bare Metal In-Stent Restenosis; TAXUS V ISR: A Prospective, Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis; TIS: Treatment of Coronary In-Stent Restenosis; WRIST: Washington Radiation for In-Stent restenosis Trial